<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Res</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Res</journal-id><journal-id journal-id-type="publisher-id">JDR</journal-id><journal-title-group><journal-title>Journal of Diabetes Research</journal-title></journal-title-group><issn pub-type="ppub">2314-6745</issn><issn pub-type="epub">2314-6753</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5618766</article-id><article-id pub-id-type="doi">10.1155/2017/5947859</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Akt/mTOR Role in Human Foetoplacental Vascular Insulin Resistance in Diseases of Pregnancy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9638-9721</contrib-id><name><surname>Villalobos-Labra</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2883-378X</contrib-id><name><surname>Silva</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1280-9128</contrib-id><name><surname>Subiabre</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0901-7672</contrib-id><name><surname>Araos</surname><given-names>Joaqu&#x000ed;n</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8218-1882</contrib-id><name><surname>Salsoso</surname><given-names>Roc&#x000ed;o</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5128-570X</contrib-id><name><surname>Fuenzalida</surname><given-names>B&#x000e1;rbara</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;ez</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Toledo</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Quezada</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pardo</surname><given-names>Fabi&#x000e1;n</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1530-0458</contrib-id><name><surname>Chiarello</surname><given-names>Delia I.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leiva</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5802-2243</contrib-id><name><surname>Sobrevia</surname><given-names>Luis</given-names></name><email>sobrevia@me.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I8">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Cat&#x000f3;lica de Chile, 8330024 Santiago, Chile</aff><aff id="I2">
<sup>2</sup>Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB Groningen, Netherlands</aff><aff id="I3">
<sup>3</sup>Department of Physiology, Faculty of Pharmacy, Universidad de Sevilla, 41012 Seville, Spain</aff><aff id="I4">
<sup>4</sup>Department of Basic Sciences, Faculty of Sciences, Universidad del B&#x000ed;o-B&#x000ed;o, 3780000 Chill&#x000e1;n, Chile</aff><aff id="I5">
<sup>5</sup>Vascular Physiology Laboratory, Department of Physiology, Faculty of Biological Sciences, Universidad de Concepci&#x000f3;n, 4070386 Concepci&#x000f3;n, Chile</aff><aff id="I6">
<sup>6</sup>Institute of Biochemistry and Microbiology, Science Faculty, Universidad Austral de Chile, 5110566 Valdivia, Chile</aff><aff id="I7">
<sup>7</sup>Metabolic Diseases Research Laboratory, Center of Research, Development and Innovation in Health-Aconcagua Valley, School of Medicine, Faculty of Medicine, Universidad de Valpara&#x000ed;so, San Felipe Campus, 2172972 San Felipe, Chile</aff><aff id="I8">
<sup>8</sup>University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine and Biomedical Sciences, University of Queensland, Herston, Brisbane, QLD 4029, Australia</aff><author-notes><fn fn-type="other"><p>Academic Editor: Christian Wadsack</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>5947859</elocation-id><history><date date-type="received"><day>1</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Roberto Villalobos-Labra et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Insulin resistance is characteristic of pregnancies where the mother shows metabolic alterations, such as preeclampsia (PE) and gestational diabetes mellitus (GDM), or abnormal maternal conditions such as pregestational maternal obesity (PGMO). Insulin signalling includes activation of insulin receptor substrates 1 and 2 (IRS1/2) as well as Src homology 2 domain-containing transforming protein 1, leading to activation of 44 and 42&#x02009;kDa mitogen-activated protein kinases and protein kinase B/Akt (Akt) signalling cascades in the human foetoplacental vasculature. PE, GDM, and PGMO are abnormal conditions coursing with reduced insulin signalling, but the possibility of the involvement of similar cell signalling mechanisms is not addressed. This review aimed to determine whether reduced insulin signalling in PE, GDM, and PGMO shares a common mechanism in the human foetoplacental vasculature. Insulin resistance in these pathological conditions results from reduced Akt activation mainly due to inhibition of IRS1/2, likely due to the increased activity of the mammalian target of rapamycin (mTOR) resulting from lower activity of adenosine monophosphate kinase. Thus, a defective signalling via Akt/mTOR in response to insulin is a central and common mechanism of insulin resistance in these diseases of pregnancy. In this review, we summarise the cell signalling mechanisms behind the insulin resistance state in PE, GDM, and PGMO focused in the Akt/mTOR signalling pathway in the human foetoplacental endothelium.</p></abstract><funding-group><award-group><funding-source>Marie Curie International Research Staff Exchange Scheme</funding-source><award-id>295185</award-id></award-group><award-group><funding-source>Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico</funding-source><award-id>11150083</award-id><award-id>3160194</award-id><award-id>1150344</award-id><award-id>1150377</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Insulin modulates D-glucose homeostasis, and a reduced response or a lack of response to this hormone (hereafter referred as &#x0201c;insulin resistance&#x0201d;) is characteristic in several pathologies, including diabetes mellitus and obesity [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Insulin resistance tightly relates with abnormal responses of the vascular endothelium, that is, endothelial dysfunction, to vasoactive molecules including insulin and the endogenous nucleoside adenosine [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. Human pregnancy courses with physiological maternal and foetal insulin resistance as an adaptive response to the increasing nutrient requirement by the pregnant women and the growing foetuses [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Insulin signalling involves preferential activation of the protein kinase B (PKB)/Akt (Akt) and mitogen-activated protein kinase (MAPK) signalling pathways [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Vascular actions of insulin in the human placenta and umbilical cord vessels (hereafter referred as &#x0201c;foetoplacental vasculature&#x0201d;) are of relevance since this vascular bed lacks innervation, and the control of the blood flux results from local release of vasoactive molecules [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. The mechanisms behind vascular insulin effects include the synthesis of nitric oxide (NO) by the endothelial NO synthase (eNOS) isoform, ATP release, and adenosine-mediated increase of L-arginine transport and NO synthesis [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Pathologies of pregnancy, such as preeclampsia (PE) [<xref rid="B10" ref-type="bibr">10</xref>] and gestational diabetes mellitus (GDM) [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B11" ref-type="bibr">11</xref>], and abnormal maternal conditions, such as pregestational maternal obesity (PGMO) and maternal obesity in pregnancy [<xref rid="B12" ref-type="bibr">12</xref>], show with reduced insulin signalling in the foetoplacental vasculature. In this review, we propose that common signalling mechanisms result in insulin resistance of the human foetoplacental vasculature in these diseases.</p></sec><sec id="sec2"><title>2. Insulin Signalling</title><p>Insulin activates the splice variants A (IR-A) and B (IR-B) of insulin receptors (IRs) in the human foetoplacental vasculature [<xref rid="B13" ref-type="bibr">13</xref>]. IR-A and IR-B are expressed in this vascular bed with IR-A showing higher affinity for insulin than that with IR-B [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. IR activation by <italic>&#x003b2;</italic>-subunit autophosphorylation recruits and phosphorylates two protein families, that is, the insulin receptor substrates (IRSs) and the Src homology 2 domain-containing transforming protein 1 (SHc) [<xref rid="B15" ref-type="bibr">15</xref>] (<xref ref-type="fig" rid="fig1">Figure 1()</xref>). IRSs have at least six members (IRS-1 to IRS-6), where IRS-1 and IRS-2 are the most characterized [<xref rid="B15" ref-type="bibr">15</xref>]. SHc corresponds to at least three different proteins (SHcA, SHcB, and SHcC), with SHcA being expressed in mammals as the alternative splicing isoforms SHcA 46, SHcA 52, and SHcA 66 [<xref rid="B16" ref-type="bibr">16</xref>]. IRS-1 and IRS-2 are major activators of Akt via phosphatidylinositol 3 kinase (PI3K) compared with a minor effect on 44 and 42&#x02009;kDa mitogen-activated protein kinases (p44/42<sup>mapk</sup>); instead, SHcA preferentially activates p44/42<sup>mapk</sup> via the growth factor receptor-bound protein 2 (Grb2) [<xref rid="B17" ref-type="bibr">17</xref>]. However, whether stimulation of IR-A or IR-B results in differential SHc or IRS activation and signalling is unknown. The physiological response of most tissues in the human body, including the foetoplacental vasculature, is that activation of p42/44<sup>mapk</sup> and Akt signalling pathways results in increased eNOS expression and activity leading to vasodilation [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B18" ref-type="bibr">18</xref>]. However, under pathological conditions, the equilibrium between signalling associated with IR-A and IR-B activation by insulin is lost and a preferential activation of p42/44<sup>mapk</sup> or Akt is reported. Several studies describe a variety of cell signalling mechanisms potentially involved in these alterations of insulin response; however, upstream- and downstream-associated signalling pathways are not addressed.</p></sec><sec id="sec3"><title>3. Insulin Resistance</title><p>Insulin resistance is seen in subjects where the metabolic handling of D-glucose is deficient [<xref rid="B2" ref-type="bibr">2</xref>]. PE [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>], GDM [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>], and obesity in pregnancy [<xref rid="B23" ref-type="bibr">23</xref>] show with insulin resistance in the mother, foetus, and newborn. However, whether insulin resistance results from or is the cause of these pathological conditions is still unclear.</p><p>Several studies show that IRS-1-mediated activation of PI3K leads to formation of phosphatidylinositol triphosphate, the substrate for the human 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt [<xref rid="B15" ref-type="bibr">15</xref>] (<xref ref-type="fig" rid="fig2">Figure 2</xref>). However, in insulin resistance, IR-B preferential activation by insulin results in IRS1/2-mediated increase in the activity of the p85<italic>&#x003b1;</italic> regulatory subunit of PI3K (PI3K p85<italic>&#x003b1;</italic>), which inhibits Akt thus reducing NO generation. Other reports show that Akt activation mediates increased activity of the mammalian target of rapamycin (mTOR), a regulator of cell proliferation, adhesion, migration, invasion, metabolism, and survival [<xref rid="B24" ref-type="bibr">24</xref>]. Interestingly, mTOR signals through p70 S6 kinase 1 (S6K1) which reduces insulin signalling by inhibiting IRSs-activity-mediated activation of Akt [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. Thus, a modulatory loop to keep a physiological Akt activity and therefore insulin signalling to cause vasodilation involves mTOR activation/deactivation depending on the state of activation of Akt. When mTOR is upregulated, the physiological consequences are reduced Akt-mediated, NO-dependent vascular responses to insulin.</p><p>Other reports address that mTOR activity is inhibited by the adenosine monophosphate kinase (AMPK) [<xref rid="B27" ref-type="bibr">27</xref>], a molecule considered as general sensor of the cell energy state getting activated in response to a lower ATP/AMP ratio [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. AMPK activation results in increased eNOS activator phosphorylation at serine 1177 (Ser<sup>1177</sup>) and serine 615 (Ser<sup>615</sup>) in the vasculature [<xref rid="B30" ref-type="bibr">30</xref>]. Interestingly, AMPK activation increased the activity of PI3K/Akt/eNOS signalling cascade leading to higher NO generation and prevented the high D-glucose-impaired response to insulin in human umbilical vein endothelial cells (HUVECs) [<xref rid="B31" ref-type="bibr">31</xref>]. Thus, it is suggested that AMPK will increase insulin signalling due to its capacity to inhibit mTOR in the human foetoplacental vasculature.</p><p>Activation of p44/42<sup>mapk</sup> triggers c-Jun N-terminal kinase (JNK) signalling in HUVECs, resulting in IRS inhibition [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>] (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Since S6K1 activation by mTOR results in p44/42<sup>mapk</sup>- and Akt-reduced activity in HUVECs [<xref rid="B34" ref-type="bibr">34</xref>] and insulin-dependent activation of p44/42<sup>mapk</sup> inhibits AMPK in the rat skeletal muscle cell line L6 [<xref rid="B35" ref-type="bibr">35</xref>], a functional dependency between p44/42<sup>mapk</sup>, AMPK, and mTOR activity may also be a phenomenon involved in impaired insulin sensitivity in the foetoplacental vasculature.</p><p>It is well described that proinflammatory cytokine tumour necrosis factor <italic>&#x003b1;</italic> (TNF<italic>&#x003b1;</italic>) [<xref rid="B36" ref-type="bibr">36</xref>] and the adipocytokine adiponectin [<xref rid="B37" ref-type="bibr">37</xref>] and leptin [<xref rid="B38" ref-type="bibr">38</xref>] play crucial roles in insulin resistance. TNF<italic>&#x003b1;</italic> activates the JNK signalling pathway in HUVECs [<xref rid="B39" ref-type="bibr">39</xref>] resulting in inhibition of IRS-1 and reduced Akt-mediated insulin signalling [<xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B42" ref-type="bibr">42</xref>] (<xref ref-type="fig" rid="fig2">Figure 2()</xref>). Interestingly, higher plasma TNF<italic>&#x003b1;</italic> is found late in pregnancy (34&#x02013;36 weeks of gestation) suggesting a likely reduced insulin biological action at this stage of pregnancy [<xref rid="B43" ref-type="bibr">43</xref>]. Adiponectin keeps insulin signalling (i.e., acts as insulin sensitizer) increasing the IRS-dependent signalling pathway by activating AMPK [<xref rid="B37" ref-type="bibr">37</xref>] and, subsequently, inhibiting mTOR [<xref rid="B44" ref-type="bibr">44</xref>]. Interestingly, a reduced plasma level of adiponectin is reported in pregnant women with diabetes mellitus [<xref rid="B36" ref-type="bibr">36</xref>]. Since the maternal plasma TNF<italic>&#x003b1;</italic> level is elevated in PE [<xref rid="B45" ref-type="bibr">45</xref>], GDM [<xref rid="B46" ref-type="bibr">46</xref>], or obese pregnant women [<xref rid="B47" ref-type="bibr">47</xref>], a potential TNF<italic>&#x003b1;</italic>-dependent inhibition of adiponectin release in insulin resistance in pregnant women, and perhaps the foetus, is likely. However, whether TNF<italic>&#x003b1;</italic> regulates adiponectin release in pregnancy is still unknown. Leptin is released in obesity in response to accumulating subcutaneous fat and increased fatty acid oxidation [<xref rid="B38" ref-type="bibr">38</xref>], a phenomenon regarded as a state of higher insulin resistance [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B48" ref-type="bibr">48</xref>]. Additionally, leptin activates JNK leading to inhibition of IRS1/2 and reduced insulin sensitivity [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Since (i) leptin also increases the generation of reactive oxygen species (ROS) in HUVECs [<xref rid="B49" ref-type="bibr">49</xref>], (ii) superoxide anion (O<sub>2</sub><sup>&#x02212;</sup>), the most reactive ROS, scavenges NO [<xref rid="B30" ref-type="bibr">30</xref>], and (iii) ROS activates JNK in this cell type [<xref rid="B49" ref-type="bibr">49</xref>], a leptin/ROS (probably O<sub>2</sub><sup>&#x02212;</sup>)/JNK pathway is likely described as a mechanism leading to reduced insulin sensitivity in the human foetoplacental vasculature. Interestingly, increased leptin concentration in the maternal circulation is reported in GDM pregnancies [<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>], a disease that also shows with increased ROS generation [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Thus, this adipocytokine may also play a role in insulin resistance particularly in diseases of pregnancy where ROS generation is increased.</p></sec><sec id="sec4"><title>4. Insulin Resistance in Pregnancy Diseases</title><sec id="sec4.1"><title>4.1. Preeclampsia</title><p>Preeclampsia (PE) is a heterogeneous pregnancy-specific multisystemic syndrome, defined by the occurrence of new onset hypertension (&#x02265;140/90&#x02009;mmHg) and proteinuria (&#x02265;300&#x02009;mg/24 hours) after 20 weeks of gestation [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B52" ref-type="bibr">52</xref>]. PE is of early onset (EOPE, &#x0003c;34 weeks of gestation) or late onset (LOPE, &#x02265;34 weeks of gestation) [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>]. EOPE and LOPE pregnancies associate with impaired insulin response of the maternal [<xref rid="B55" ref-type="bibr">55</xref>] and foetoplacental vasculature [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B56" ref-type="bibr">56</xref>]. However, not a clear mechanism explaining these alterations in EOPE and LOPE is yet available.</p><p>Preferential activation of p42/44<sup>mapk</sup> and Akt is described in the foetoplacental vasculature from PE. Preterm PE (&#x0003c;37&#x02009;wg) with HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelet count) courses with increased phosphorylated p42/44<sup>mapk</sup> activation in villous trophoblast [<xref rid="B57" ref-type="bibr">57</xref>]. In addition, the maternal plasma level from women with EOPE shows a higher level of endothelin-1 (ET-1) [<xref rid="B58" ref-type="bibr">58</xref>], but reduced Akt activity in the placenta [<xref rid="B59" ref-type="bibr">59</xref>] (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Thus, an ET-1-dependent inhibition of Akt reducing insulin signalling is likely in this disease. Furthermore, since Akt activity positively correlates with NO generation in human foetal endothelial cells [<xref rid="B60" ref-type="bibr">60</xref>], EOPE-associated foetoplacental vascular dysfunction due to reduced NOS activity may involve p44/42<sup>mapk</sup>/ET-1/Akt signalling. On the other hand, LOPE pregnancies show with unaltered p42/44<sup>mapk</sup> [<xref rid="B57" ref-type="bibr">57</xref>] and unaltered [<xref rid="B57" ref-type="bibr">57</xref>] or decreased [<xref rid="B61" ref-type="bibr">61</xref>] Akt activity in the placenta. Intriguingly, eNOS protein abundance and activator phosphorylation (Ser<sup>1177</sup>) are higher in HUVECs from LOPE pregnancies [<xref rid="B20" ref-type="bibr">20</xref>], findings complemented by elevated nitrate/nitrite ratio in human umbilical vein serum [<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>], but contrary to the reported lower nitrate/nitrite ratio [<xref rid="B64" ref-type="bibr">64</xref>] and NOS-generation of L-citrulline from L-arginine (index of NOS activity) [<xref rid="B20" ref-type="bibr">20</xref>] in this cell type. One plausible explanation for reduced NOS activity in HUVECs from LOPE pregnancies is a predominant functional effect of an increase of eNOS inhibitor (Thr<sup>495</sup>) compared with the effect of an activator (Ser<sup>1177</sup>) phosphorylation of this enzyme [<xref rid="B20" ref-type="bibr">20</xref>]. Earlier studies show increased IRS-1 (Ser<sup>312</sup>) and IRS-2 (Ser<sup>731</sup>) inhibitor phosphorylation in response to insulin in the placenta from LOPE pregnancies [<xref rid="B65" ref-type="bibr">65</xref>]. Since IRS1/2 are key activators of Akt, LOPE-reduced Akt and NOS activity could involve IRS1/2 inhibition. Thus, LOPE-associated impaired insulin response could result from reduced IRS1/2/Akt/eNOS signalling in the human foetoplacental vasculature. Since activation of mTOR results in reduced IRS1/2 activity, it is likely that this signalling molecule is involved in the effect of EOPE and LOPE on NOS activity. However, there is no information regarding the potential role of mTOR in the aetiology of EOPE or LOPE in this vascular bed.</p><p>Several reports support the involvement of circulating factors in the aetiology of PE including increased soluble Fms-like tyrosine kinase 1 (sFlt1), soluble endoglin (sEng), and reduced vascular endothelial growth factor (VEGF) plasma levels [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>]. The increased plasma levels of ET-1 and sEng result in a higher sFlt1 plasma level [<xref rid="B68" ref-type="bibr">68</xref>]. The latter reduces the availability of free VEGF-A to bind VEGF plasma membrane receptors and inhibition of PI3K/Akt signalling, including eNOS activity, in HUVECs [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B69" ref-type="bibr">69</xref>]. However, inhibition of the PI3K/Akt signalling does not alter sEng release from placenta explants or primary trophoblast in PE [<xref rid="B59" ref-type="bibr">59</xref>]; therefore, a differential response to PI3K/Akt-mediated insulin signalling in human foetoplacental endothelium versus trophoblast is likely. Interestingly, PI3K p85 phosphorylation at Tyr<sup>688</sup> results in increased PI3K activity and Akt signalling in placental tissue from EOPE pregnancies [<xref rid="B70" ref-type="bibr">70</xref>]. The latter was proposed as a compensatory mechanism to the VEGF-reduced activation of PI3K/Akt signalling in this disease. However, PI3K p85 activator phosphorylation is unaltered in placentas from LOPE pregnancies [<xref rid="B71" ref-type="bibr">71</xref>], suggesting a different adaptive mechanism for insulin signalling in EOPE and LOPE pregnancies.</p></sec><sec id="sec4.2"><title>4.2. Gestational Diabetes Mellitus</title><p>GDM refers to any degree of glucose intolerance first recognized during pregnancy, diagnosed at 24&#x02013;28 weeks of gestation [<xref rid="B2" ref-type="bibr">2</xref>]. GDM associates with maternal obesity [<xref rid="B72" ref-type="bibr">72</xref>] and high risk of the mother to develop T2DM [<xref rid="B73" ref-type="bibr">73</xref>]. GDM presents with clinical manifestations in the mother [<xref rid="B74" ref-type="bibr">74</xref>], foetus [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>], and newborn [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>], including hyperglycaemia and hyperinsulinemia (see also [<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>]). It is reported that IR-A expression and insulin receptor <italic>&#x003b2;</italic>-subunit (<italic>&#x003b2;</italic>-IR) activity are increased in HUVECs from GDM [<xref rid="B80" ref-type="bibr">80</xref>] (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Interestingly, the ratio for p44/42<sup>mapk</sup>/Akt is &#x0003e;1 due to increased p44/44<sup>mapk</sup>, but unaltered Akt activity, suggesting preferential activation of IR-A in this cell type. However, reduced IR-A, but increased IR-B expression, with a p44/42<sup>mapk</sup>/Akt ratio&#x02009;&#x0003c;&#x02009;1 was reported in human placental microvascular endothelium. Insulin restored IR-A and IR-B expression and p44/42<sup>mapk</sup>/Akt ratio suggesting differential activation of insulin signalling cascades due to differential activation of IR subtypes in the macrovascular and microvascular foetoplacental endothelium from GDM pregnancies.</p><p>GDM associates with reduced uptake of the endogenous nucleoside adenosine, a potent vasodilator in most tissues, including the foetoplacental vasculature [<xref rid="B4" ref-type="bibr">4</xref>]. This phenomenon results in elevated extracellular concentration of adenosine enough to activate adenosine receptors [<xref rid="B81" ref-type="bibr">81</xref>], preferentially A<sub>2A</sub> adenosine receptors (A<sub>2A</sub>AR), in the foetoplacental endothelium from GDM pregnancies [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Interestingly, GDM also increases hCAT-1-mediated L-arginine transport in HUVECs [<xref rid="B82" ref-type="bibr">82</xref>], which seems to link with an increased eNOS activity and NO synthesis in this cell type. The latter study also shows that insulin reversed the GDM-increased L-arginine transport requiring A<sub>1</sub>AR activation. Thus, different adenosine receptors are involved in the modulation of L-arginine transport in HUVECs from normal compared with GDM pregnancies.</p><p>AMPK activation is lower in the placenta from women with GDM [<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>]. This finding is complemented by high levels of TNF-<italic>&#x003b1;</italic> and activation of NF-<italic>&#x003ba;</italic>B, conditions leading to increased synthesis of mediators of inflammation and impaired insulin action [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. Thus, reduced AMPK expression could associate with a proinflammatory state and insulin resistance in GDM pregnancies. Since AMPK inhibits mTOR activity [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B44" ref-type="bibr">44</xref>], a reduced AMPK activation could result in increased mTOR activity in GDM. GDM also courses with hyperleptinemia in the placenta [<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>] and reduced adiponectin level [<xref rid="B89" ref-type="bibr">89</xref>] in umbilical vein plasma. However, precise mechanisms at insulin signalling in this disease are unclear.</p><p>Insulin treatment of women with GDM (i.e., patients under insulin therapy) reverses the GDM-associated maternal and foetal hyperglycaemia and the increase in IRS-1 and PI3K p85<italic>&#x003b1;</italic> activity caused by this disease to values in normal pregnancies [<xref rid="B90" ref-type="bibr">90</xref>]. However, the elevated level of leptin in the foetal plasma and TNF-<italic>&#x003b1;</italic> and IL-1<italic>&#x003b2;</italic> levels in the placenta from GDM pregnancies were unaltered by insulin therapy. Thus, insulin therapy results in normalization of foetal and maternal glycaemia but does not restore the impaired insulin signalling in foetoplacental endothelium in this disease. Indeed, we recently reported that insulin therapy in women with GDM did not restore the increased L-arginine uptake and NO synthesis seen in HUVECs from women with GDM under a controlled diet [<xref rid="B91" ref-type="bibr">91</xref>]. It is worrying that a higher chance to be born large for gestational age is reported as an outcome for insulin therapy [<xref rid="B92" ref-type="bibr">92</xref>] or in pregnant women treated with insulin and metformin [<xref rid="B93" ref-type="bibr">93</xref>] and in a larger number (~25%) of infants showing one or more episodes with neonatal morbidity where neonatal asymptomatic hypoglycaemia was the most frequent [<xref rid="B94" ref-type="bibr">94</xref>]. We emphasize our call regarding the still unclear effect of maternal insulin therapy on foetus development, the newborn, and postnatal life [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B95" ref-type="bibr">95</xref>].</p></sec><sec id="sec4.3"><title>4.3. Pregestational Maternal Obesity</title><p>The World Health Organization defines obesity as individuals with a body mass index (BMI)&#x02009;&#x0003e;&#x02009;30&#x02009;kg/m<sup>2</sup>, a disease that has reached epidemic characteristics worldwide [<xref rid="B1" ref-type="bibr">1</xref>]. One of the main risks of an abnormal nutritional state is its association with metabolic syndrome, a condition with high multiple risk factors for chronic diseases, including diabetes mellitus, cardiovascular diseases, stroke, hypertension, and cancer [<xref rid="B96" ref-type="bibr">96</xref>].</p><p>Few studies address cell signalling in PGMO. Epidemiological evidence shows that children born to PGMO pregnancies show hyperinsulinemia and elevated insulin resistance [<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>]. Additionally, infants and adolescents from PGMO pregnancies exhibit high risk of developing obesity [<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>] and associate with higher cardiovascular risk in adulthood [<xref rid="B100" ref-type="bibr">100</xref>]. Interestingly, umbilical cords from PGMO pregnancies show a gene profile related with reduced insulin sensitivity [<xref rid="B101" ref-type="bibr">101</xref>], including downregulation of <italic>PDPK1</italic> (coding for PDK1) involved in D-glucose uptake and storage [<xref rid="B101" ref-type="bibr">101</xref>]. However, direct functional evidence for insulin effect on foetoplacental endothelium in PGMO is limited (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>PGMO pregnancies associate with reduced activity of AMPK [<xref rid="B102" ref-type="bibr">102</xref>] but increased activity of mTOR [<xref rid="B103" ref-type="bibr">103</xref>] in the placenta. These findings correlate with reduced maternal plasma adiponectin levels [<xref rid="B104" ref-type="bibr">104</xref>]. Since JNK activation is also increased in human placentas from PGMO pregnancies [<xref rid="B105" ref-type="bibr">105</xref>], a potential insulin resistance condition resulting from IRS inhibition may involve adiponectin-reduced level-dependent AMPK inactivation, increased mTOR activity, and reduced Akt signalling, in this abnormal condition of pregnancy (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec></sec><sec id="sec5"><title>5. Concluding Comments</title><p>Insulin regulates canonical signal transduction pathways initiated by activation of IR-A/p44/42<sup>mapk</sup> and IR-B/Akt in human foetoplacental vasculature in healthy pregnancies (<xref ref-type="fig" rid="fig3">Figure 3</xref>). IRS-1 and IRS-2 are upstream activators of the PI3K/Akt signalling pathway leading to activation of mTOR. SHcA 42 and SHcA 56 activate p44/42<sup>mapk</sup> leading to increased release of vasoconstrictors, such as ET-1. Insulin resistance associated with PGMO, PE, and GDM results in foetoplacental vascular dysfunction and altered vascular reactivity to insulin. A likely potential common point in insulin resistance in these diseases is a reduced Akt signalling resulting in lower activation of mTOR and eNOS. A role for AMPK in this phenomenon is not clear, but the involvement of this molecule is likely since its activation positively correlates with mTOR activity. A role of NO in the response to insulin in the foetoplacental endothelium in diseases of pregnancy is well described [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Thus, modulation of NO generation could be a final target of an abnormal IR-A/SHcA/p44/42<sup>mapk</sup>- and IR-B/IRSs/Akt-mediated signalling via Akt/mTOR in insulin resistance at the human foetoplacental vasculature. A therapy targeting these signalling molecules could be beneficial to improve insulin response in these diseases. PGMO is a risk factor for developing PE [<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>] and GDM [<xref rid="B107" ref-type="bibr">107</xref>]. Thus, characterizing potential common signalling mechanisms for PGMO, PE, and GDM will facilitate the design of an approach to prevent insulin resistance in the co-occurrence of these or other disorders in pregnancy, thus reducing or abolishing their deleterious consequences for the mother, the foetus, and the newborn.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Mrs. Amparo Pacheco from CMPL, Pontificia Universidad Cat&#x000f3;lica de Chile (PUC), for the excellent technical and secretarial assistance. This work was supported by the Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico (FONDECYT 1150377, 1150344, 3160194, 11150083), Chile. This project has received funding from the Marie Curie International Research Staff Exchange Scheme with the 7th European Community Framework Program (Grant Agreement no. 295185&#x02013;EULAMDIMA), the Netherlands. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Tamara S&#x000e1;ez, and Roc&#x000ed;o Salsoso hold the Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n en Ciencia y Tecnolog&#x000ed;a (CONICYT) PhD fellowships (Chile). Roc&#x000ed;o Salsoso, Luis Silva, and B&#x000e1;rbara Fuenzalida hold Faculty of Medicine, PUC&#x02013;PhD fellowships (Chile). Tamara S&#x000e1;ez and Luis Silva hold UMCG University of Groningen Postgraduate School-PhD fellowships (the Netherlands).</p></ack><sec><title>Conflicts of Interest</title><p>The authors confirm that there are no conflicts of interest.</p></sec><sec><title>Authors' Contributions</title><p>Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia conceived and designed the study. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Joaqu&#x000ed;n Araos, Tamara S&#x000e1;ez, B&#x000e1;rbara Fuenzalida, Marcelo Gonz&#x000e1;lez, Roc&#x000ed;o Salsoso, and Andrea Leiva acquired the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Fernando Toledo, Delia I. Chiarello, Joaqu&#x000ed;n Araos, Tamara S&#x000e1;ez, B&#x000e1;rbara Fuenzalida, Marcelo Gonz&#x000e1;lez, Fab&#x000ed;an Pardo, Roc&#x000ed;o Salsoso, Claudia Quezada, Andrea Leiva, and Luis Sobrevia analyzed the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Roc&#x000ed;o Salsoso, Joaqu&#x000ed;n Araos, B&#x000e1;rbara Fuenzalida, Fab&#x000ed;an Pardo, Claudia Quezada, Andrea Leiva, and Luis Sobrevia interpreted the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Roc&#x000ed;o Salsoso, and Luis Sobrevia compiled the tables. Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia designed the figures. Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia wrote the manuscript.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>American Diabetes Association (ADA)</collab><article-title>Classification and diagnosis of diabetes</article-title><source><italic>Diabetes Care</italic></source><year>2017</year><volume>40</volume><fpage>S11</fpage><lpage>S24</lpage><pub-id pub-id-type="pmid">27979889</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>World Health Organization (WHO)</collab><article-title>Global status report on noncommunicable diseases 2014</article-title><source><italic>World Health</italic></source><year>2014</year><volume>176</volume></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muniyappa</surname><given-names>R.</given-names></name><name><surname>Sowers</surname><given-names>J. R.</given-names></name></person-group><article-title>Role of insulin resistance in endothelial dysfunction</article-title><source><italic>Reviews in Endocrine &#x00026; Metabolic Disorders</italic></source><year>2013</year><volume>14</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s11154-012-9229-1</pub-id><pub-id pub-id-type="other">2-s2.0-84874649487</pub-id><?supplied-pmid 23306778?><pub-id pub-id-type="pmid">23306778</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>L.</given-names></name><name><surname>Subiabre</surname><given-names>M.</given-names></name><name><surname>Araos</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Insulin/adenosine axis linked signalling</article-title><source><italic>Molecular Aspects of Medicine</italic></source><year>2017</year><volume>55</volume><fpage>45</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2016.11.002</pub-id><pub-id pub-id-type="other">2-s2.0-85007275375</pub-id><?supplied-pmid 27871900?><pub-id pub-id-type="pmid">27871900</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonagra</surname><given-names>A. D.</given-names></name><name><surname>Biradar</surname><given-names>S. M.</given-names></name><name><surname>Dattatreya</surname><given-names>K.</given-names></name><name><surname>Murthy</surname><given-names>D. S. J.</given-names></name></person-group><article-title>Normal pregnancy- a state of insulin resistance</article-title><source><italic>Journal of Clinical and Diagnostic Research</italic></source><year>2014</year><volume>8</volume><fpage>CC01</fpage><lpage>CC03</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2014/10068.5081</pub-id><?supplied-pmid 25584208?><pub-id pub-id-type="pmid">25584208</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mather</surname><given-names>K. J.</given-names></name><name><surname>Steinberg</surname><given-names>H. O.</given-names></name><name><surname>Baron</surname><given-names>A. D.</given-names></name></person-group><article-title>Insulin resistance in the vasculature</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2013</year><volume>123</volume><fpage>1003</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1172/JCI67166</pub-id><pub-id pub-id-type="other">2-s2.0-84874599002</pub-id><?supplied-pmid 23454764?><pub-id pub-id-type="pmid">23454764</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>S. B.</given-names></name><name><surname>Khong</surname><given-names>T. Y.</given-names></name></person-group><article-title>Lack of innervation of human umbilical cord. An immunohistological and histochemical study</article-title><source><italic>Placenta</italic></source><year>1990</year><volume>11</volume><fpage>59</fpage><lpage>62</lpage><?supplied-pmid 2326237?><pub-id pub-id-type="pmid">2326237</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>M. S.</given-names></name><name><surname>Stephenson</surname><given-names>A. H.</given-names></name><name><surname>Bowles</surname><given-names>E. A.</given-names></name><name><surname>Sprague</surname><given-names>R. S.</given-names></name></person-group><article-title>Insulin inhibits human erythrocyte cAMP accumulation and ATP release: role of phosphodiesterase 3 and phosphoinositide 3-kinase</article-title><source><italic>Experimental Biology and Medicine</italic></source><year>2010</year><volume>235</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1258/ebm.2009.009206</pub-id><pub-id pub-id-type="other">2-s2.0-77649159288</pub-id><?supplied-pmid 20404042?><pub-id pub-id-type="pmid">20404042</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobrevia</surname><given-names>L.</given-names></name><name><surname>Salsoso</surname><given-names>R.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>T.</given-names></name><name><surname>Sanhueza</surname><given-names>C.</given-names></name><name><surname>Pardo</surname><given-names>F.</given-names></name><name><surname>Leiva</surname><given-names>A.</given-names></name></person-group><article-title>Insulin therapy and fetoplacental vascular function in gestational diabetes mellitus</article-title><source><italic>Experimental Physiology</italic></source><year>2015</year><volume>100</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1113/expphysiol.2014.082743</pub-id><pub-id pub-id-type="other">2-s2.0-84923547655</pub-id><?supplied-pmid 25581778?><pub-id pub-id-type="pmid">25581778</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salsoso</surname><given-names>R.</given-names></name><name><surname>Far&#x000ed;as</surname><given-names>M.</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Adenosine and preeclampsia</article-title><source><italic>Molecular Aspects of Medicine</italic></source><year>2017</year><volume>55</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2016.12.003</pub-id><pub-id pub-id-type="pmid">28089907</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonioli</surname><given-names>L.</given-names></name><name><surname>Blandizzi</surname><given-names>C.</given-names></name><name><surname>Cs&#x000f3;ka</surname><given-names>B.</given-names></name><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Hask&#x000f3;</surname><given-names>G.</given-names></name></person-group><article-title>Adenosine signalling in diabetes mellitus&#x02014;pathophysiology and therapeutic considerations</article-title><source><italic>Nature Reviews. Endocrinology</italic></source><year>2015</year><volume>11</volume><fpage>228</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2015.10</pub-id><pub-id pub-id-type="other">2-s2.0-84925849428</pub-id><?supplied-pmid 25687993?><pub-id pub-id-type="pmid">25687993</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>F.</given-names></name><name><surname>Villalobos-Labra</surname><given-names>R.</given-names></name><name><surname>Chiarello</surname><given-names>D. I.</given-names></name><etal/></person-group><article-title>Molecular implications of adenosine in obesity</article-title><source><italic>Molecular Aspects of Medicine</italic></source><year>2017</year><volume>55</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2017.01.003</pub-id><pub-id pub-id-type="pmid">28104382</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermeier</surname><given-names>F.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>T.</given-names></name><name><surname>Arroyo</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Insulin receptor isoforms: an integrated view focused on gestational diabetes mellitus</article-title><source><italic>Diabetes/Metabolism Research and Reviews</italic></source><year>2016</year><volume>32</volume><fpage>350</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1002/dmrr.2729</pub-id><pub-id pub-id-type="other">2-s2.0-84949599728</pub-id><?supplied-pmid 26431063?><pub-id pub-id-type="pmid">26431063</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosthaf</surname><given-names>L.</given-names></name><name><surname>Grako</surname><given-names>K.</given-names></name><name><surname>Dull</surname><given-names>T. J.</given-names></name><name><surname>Coussens</surname><given-names>L.</given-names></name><name><surname>Ullrich</surname><given-names>A.</given-names></name><name><surname>DA</surname><given-names>M. C.</given-names></name></person-group><article-title>Functionally distinct insulin receptors generated by tissue-specific alternative splicing</article-title><source><italic>The EMBO Journal</italic></source><year>1990</year><volume>9</volume><fpage>2409</fpage><lpage>2413</lpage><?supplied-pmid 2369896?><pub-id pub-id-type="pmid">2369896</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>J.</given-names></name><name><surname>Kleinridders</surname><given-names>A.</given-names></name><name><surname>Kahn</surname><given-names>C. R.</given-names></name></person-group><article-title>Insulin receptor signaling in normal and insulin-resistant states</article-title><source><italic>Cold Spring Harbor Perspectives in Biology</italic></source><year>2014</year><volume>6, article a009191</volume><pub-id pub-id-type="doi">10.1101/cshperspect.a009191</pub-id><pub-id pub-id-type="other">2-s2.0-84891648237</pub-id><?supplied-pmid 24384568?><pub-id pub-id-type="pmid">24384568</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravichandran</surname><given-names>K. S.</given-names></name></person-group><article-title>Signaling via Shc family adapter proteins</article-title><source><italic>Oncogene</italic></source><year>2001</year><volume>20</volume><fpage>6322</fpage><lpage>6330</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204776</pub-id><pub-id pub-id-type="other">2-s2.0-0035474473</pub-id><?supplied-pmid 11607835?><pub-id pub-id-type="pmid">11607835</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>S. H.</given-names></name><name><surname>Hadari</surname><given-names>Y. R.</given-names></name><name><surname>Gotoh</surname><given-names>N.</given-names></name><name><surname>Guy</surname><given-names>G. R.</given-names></name><name><surname>Schlessinger</surname><given-names>J.</given-names></name><name><surname>Lax</surname><given-names>I.</given-names></name></person-group><article-title>Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2001</year><volume>98</volume><fpage>6074</fpage><lpage>6079</lpage><pub-id pub-id-type="doi">10.1073/pnas.111114298</pub-id><pub-id pub-id-type="other">2-s2.0-0035933094</pub-id><?supplied-pmid 11353842?><pub-id pub-id-type="pmid">11353842</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobrevia</surname><given-names>L.</given-names></name><name><surname>Salsoso</surname><given-names>R.</given-names></name><name><surname>Fuenzalida</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Insulin is a key modulator of fetoplacental endothelium metabolic disturbances in gestational diabetes mellitus</article-title><source><italic>Frontiers in Physiology</italic></source><year>2016</year><volume>7</volume><fpage>p. 119</fpage><pub-id pub-id-type="doi">10.3389/fphys.2016.00119</pub-id><pub-id pub-id-type="other">2-s2.0-84964677457</pub-id><?supplied-pmid 27065887?><pub-id pub-id-type="pmid">27065887</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>J. M.</given-names></name><name><surname>Bodnar</surname><given-names>L. M.</given-names></name><name><surname>Patrick</surname><given-names>T. E.</given-names></name><name><surname>Powers</surname><given-names>R. W.</given-names></name></person-group><article-title>The role of obesity in preeclampsia</article-title><source><italic>Pregnancy Hypertens</italic></source><year>2011</year><volume>1</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.preghy.2010.10.013</pub-id><pub-id pub-id-type="other">2-s2.0-78751500843</pub-id><pub-id pub-id-type="pmid">21532964</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salsoso</surname><given-names>R.</given-names></name><name><surname>Guzm&#x000e1;n-Guti&#x000e9;rrez</surname><given-names>E.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Insulin restores l-arginine transport requiring adenosine receptors activation in umbilical vein endothelium from late-onset preeclampsia</article-title><source><italic>Placenta</italic></source><year>2015</year><volume>36</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2014.12.007</pub-id><pub-id pub-id-type="other">2-s2.0-84922935833</pub-id><?supplied-pmid 25573092?><pub-id pub-id-type="pmid">25573092</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermeier</surname><given-names>F.</given-names></name><name><surname>Salom&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Insulin restores gestational diabetes mellitus-reduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein endothelium</article-title><source><italic>Diabetes</italic></source><year>2011</year><volume>60</volume><fpage>1677</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.2337/db11-0155</pub-id><pub-id pub-id-type="other">2-s2.0-79959405707</pub-id><?supplied-pmid 21515851?><pub-id pub-id-type="pmid">21515851</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Higher fetal insulin resistance in Chinese pregnant women with gestational diabetes mellitus and correlation with maternal insulin resistance</article-title><source><italic>PLoS One</italic></source><year>2013</year><volume>8, article e59845</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0059845</pub-id><pub-id pub-id-type="other">2-s2.0-84875648365</pub-id><?supplied-pmid 23560057?><pub-id pub-id-type="pmid">23560057</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>F.</given-names></name><name><surname>Silva</surname><given-names>L.</given-names></name><name><surname>S&#x000e1;ez</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Human supraphysiological gestational weight gain and fetoplacental vascular dysfunction</article-title><source><italic>International Journal of Obesity</italic></source><year>2015</year><volume>39</volume><fpage>1264</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1038/ijo.2015.57</pub-id><pub-id pub-id-type="other">2-s2.0-84938747177</pub-id><?supplied-pmid 25869606?><pub-id pub-id-type="pmid">25869606</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karar</surname><given-names>J.</given-names></name><name><surname>Maity</surname><given-names>A.</given-names></name></person-group><article-title>PI3K/AKT/mTOR pathway in angiogenesis</article-title><source><italic>Frontiers in Molecular Neuroscience</italic></source><year>2011</year><volume>4</volume><fpage>p. 51</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2011.00051</pub-id><?supplied-pmid 22144946?><pub-id pub-id-type="pmid">22144946</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzatsos</surname><given-names>A.</given-names></name></person-group><article-title>Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2009</year><volume>284</volume><fpage>22525</fpage><lpage>22534</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.027748</pub-id><pub-id pub-id-type="other">2-s2.0-69249109628</pub-id><?supplied-pmid 19561084?><pub-id pub-id-type="pmid">19561084</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. J.</given-names></name><name><surname>DeStefano</surname><given-names>M. A.</given-names></name><name><surname>Oh</surname><given-names>W. J.</given-names></name><etal/></person-group><article-title>mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8</article-title><source><italic>Molecular Cell</italic></source><year>2012</year><volume>48</volume><fpage>875</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.09.029</pub-id><pub-id pub-id-type="other">2-s2.0-84871703377</pub-id><?supplied-pmid 23142081?><pub-id pub-id-type="pmid">23142081</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihaylova</surname><given-names>M. M.</given-names></name><name><surname>Shaw</surname><given-names>R. J.</given-names></name></person-group><article-title>The AMPK signalling pathway coordinates cell growth, autophagy and metabolism</article-title><source><italic>Nature Cell Biology</italic></source><year>2011</year><volume>13</volume><fpage>1016</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1038/ncb2329</pub-id><pub-id pub-id-type="other">2-s2.0-80052511813</pub-id><?supplied-pmid 21892142?><pub-id pub-id-type="pmid">21892142</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisslthaler</surname><given-names>B.</given-names></name><name><surname>Fleming</surname><given-names>I.</given-names></name></person-group><article-title>Activation and signaling by the AMP-activated protein kinase in endothelial cells</article-title><source><italic>Circulation Research</italic></source><year>2009</year><volume>105</volume><fpage>114</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.201590</pub-id><pub-id pub-id-type="other">2-s2.0-68049103917</pub-id><?supplied-pmid 19608989?><pub-id pub-id-type="pmid">19608989</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>D. G.</given-names></name><name><surname>Ross</surname><given-names>F. A.</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hawley</surname><given-names>S. A.</given-names></name></person-group><article-title>AMPK: a nutrient and energy sensor that maintains energy homeostasis</article-title><source><italic>Nature Reviews. Molecular Cell Biology</italic></source><year>2012</year><volume>13</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nrm3311</pub-id><pub-id pub-id-type="other">2-s2.0-84858782079</pub-id><?supplied-pmid 22436748?><pub-id pub-id-type="pmid">22436748</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>I.</given-names></name></person-group><article-title>Molecular mechanisms underlying the activation of eNOS</article-title><source><italic>Pflugers Archiv-European Journal of Physiology</italic></source><year>2010</year><volume>459</volume><fpage>793</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1007/s00424-009-0767-7</pub-id><pub-id pub-id-type="other">2-s2.0-77955285843</pub-id><?supplied-pmid 20012875?><pub-id pub-id-type="pmid">20012875</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ido</surname><given-names>Y.</given-names></name><name><surname>Carling</surname><given-names>D.</given-names></name><name><surname>Ruderman</surname><given-names>N.</given-names></name></person-group><article-title>Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation</article-title><source><italic>Diabetes</italic></source><year>2002</year><volume>51</volume><fpage>159</fpage><lpage>167</lpage><?supplied-pmid 11756336?><pub-id pub-id-type="pmid">11756336</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreozzi</surname><given-names>F.</given-names></name><name><surname>Laratta</surname><given-names>E.</given-names></name><name><surname>Sciacqua</surname><given-names>A.</given-names></name><name><surname>Perticone</surname><given-names>F.</given-names></name><name><surname>Sesti</surname><given-names>G.</given-names></name></person-group><article-title>Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells</article-title><source><italic>Circulation Research</italic></source><year>2004</year><volume>94</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000126501.34994.96</pub-id><pub-id pub-id-type="other">2-s2.0-2442691522</pub-id><?supplied-pmid 15044323?><pub-id pub-id-type="pmid">15044323</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Nigris</surname><given-names>V.</given-names></name><name><surname>Pujadas</surname><given-names>G.</given-names></name><name><surname>La Sala</surname><given-names>L.</given-names></name><name><surname>Testa</surname><given-names>R.</given-names></name><name><surname>Genovese</surname><given-names>S.</given-names></name><name><surname>Ceriello</surname><given-names>A.</given-names></name></person-group><article-title>Short-term high glucose exposure impairs insulin signaling in endothelial cells</article-title><source><italic>Cardiovascular Diabetology</italic></source><year>2015</year><volume>14</volume><fpage>p. 114</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0278-0</pub-id><pub-id pub-id-type="other">2-s2.0-84939527014</pub-id><?supplied-pmid 26297582?><pub-id pub-id-type="pmid">26297582</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegatta</surname><given-names>F.</given-names></name><name><surname>Catapano</surname><given-names>A. L.</given-names></name><name><surname>Luzi</surname><given-names>L.</given-names></name><name><surname>Terruzzi</surname><given-names>I.</given-names></name></person-group><article-title>In human endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 phosphorylation by an mTOR-dependent mechanism</article-title><source><italic>Journal of Cardiovascular Pharmacology</italic></source><year>2006</year><volume>47</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1097/01.fjc.0000211751.01326.fa</pub-id><pub-id pub-id-type="other">2-s2.0-33748145104</pub-id><?supplied-pmid 16775502?><pub-id pub-id-type="pmid">16775502</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S. L.</given-names></name><name><surname>Jeong</surname><given-names>Y. T.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2013</year><volume>169</volume><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/bph.12124</pub-id><pub-id pub-id-type="other">2-s2.0-84876215872</pub-id><?supplied-pmid 23373714?><pub-id pub-id-type="pmid">23373714</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbour</surname><given-names>L. A.</given-names></name><name><surname>McCurdy</surname><given-names>C. E.</given-names></name><name><surname>Hernandez</surname><given-names>T. L.</given-names></name><name><surname>Kirwan</surname><given-names>J. P.</given-names></name><name><surname>Catalano</surname><given-names>P. M.</given-names></name><name><surname>Friedman</surname><given-names>J. E.</given-names></name></person-group><article-title>Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes</article-title><source><italic>Diabetes Care</italic></source><year>2007</year><volume>30</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.2337/dc07-s202</pub-id><pub-id pub-id-type="other">2-s2.0-34447119409</pub-id><?supplied-pmid 17596458?><pub-id pub-id-type="pmid">17596458</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>L. Q.</given-names></name></person-group><article-title>Adiponectin signaling and function in insulin target tissues</article-title><source><italic>Journal of Molecular Cell Biology</italic></source><year>2016</year><volume>8</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjw014</pub-id><pub-id pub-id-type="other">2-s2.0-84965020589</pub-id><?supplied-pmid 26993044?><pub-id pub-id-type="pmid">26993044</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>A.</given-names></name><name><surname>Kataria</surname><given-names>M. A.</given-names></name><name><surname>Saini</surname><given-names>V.</given-names></name><name><surname>Yadav</surname><given-names>A.</given-names></name></person-group><article-title>Role of leptin and adiponectin in insulin resistance</article-title><source><italic>Clinica Chimica Acta</italic></source><year>2013</year><volume>417</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2012.12.007</pub-id><pub-id pub-id-type="other">2-s2.0-84872515944</pub-id><?supplied-pmid 23266767?><pub-id pub-id-type="pmid">23266767</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surapisitchat</surname><given-names>J.</given-names></name><name><surname>Hoefen</surname><given-names>R. J.</given-names></name><name><surname>Pi</surname><given-names>X.</given-names></name><name><surname>Yoshizumi</surname><given-names>M.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Berk</surname><given-names>B. C.</given-names></name></person-group><article-title>Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2001</year><volume>98</volume><fpage>6476</fpage><lpage>6481</lpage><pub-id pub-id-type="doi">10.1073/pnas.101134098</pub-id><pub-id pub-id-type="other">2-s2.0-0035933127</pub-id><?supplied-pmid 11353829?><pub-id pub-id-type="pmid">11353829</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre</surname><given-names>V.</given-names></name><name><surname>Uchida</surname><given-names>T.</given-names></name><name><surname>Yenush</surname><given-names>L.</given-names></name><name><surname>Davis</surname><given-names>R.</given-names></name><name><surname>White</surname><given-names>M. F.</given-names></name></person-group><article-title>The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><fpage>9047</fpage><lpage>9054</lpage><?supplied-pmid 10722755?><pub-id pub-id-type="pmid">10722755</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y. H.</given-names></name><name><surname>Giraud</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>R. J.</given-names></name><name><surname>White</surname><given-names>M. F.</given-names></name></person-group><article-title>c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><fpage>2896</fpage><lpage>2902</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208359200</pub-id><pub-id pub-id-type="other">2-s2.0-0037474274</pub-id><?supplied-pmid 12417588?><pub-id pub-id-type="pmid">12417588</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiratani</surname><given-names>K.</given-names></name><name><surname>Haruta</surname><given-names>T.</given-names></name><name><surname>Tani</surname><given-names>A.</given-names></name><name><surname>Kawahara</surname><given-names>J.</given-names></name><name><surname>Usui</surname><given-names>I.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name></person-group><article-title>Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2005</year><volume>335</volume><fpage>836</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.07.152</pub-id><pub-id pub-id-type="other">2-s2.0-23944475571</pub-id><?supplied-pmid 16099428?><pub-id pub-id-type="pmid">16099428</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirwan</surname><given-names>J. P.</given-names></name><name><surname>Hauguel-De Mouzon</surname><given-names>S.</given-names></name><name><surname>Lepercq</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TNF-alpha is a predictor of insulin resistance in human pregnancy</article-title><source><italic>Diabetes</italic></source><year>2002</year><volume>51</volume><fpage>2207</fpage><lpage>2213</lpage><?supplied-pmid 12086951?><pub-id pub-id-type="pmid">12086951</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lihn</surname><given-names>A. S.</given-names></name><name><surname>Pedersen</surname><given-names>S. B.</given-names></name><name><surname>Richelsen</surname><given-names>B.</given-names></name></person-group><article-title>Adiponectin: action, regulation and association to insulin sensitivity</article-title><source><italic>Obesity Reviews</italic></source><year>2005</year><volume>6</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1467-789X.2005.00159.x</pub-id><pub-id pub-id-type="other">2-s2.0-12444304182</pub-id><?supplied-pmid 15655035?><pub-id pub-id-type="pmid">15655035</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huda</surname><given-names>S. S.</given-names></name><name><surname>Brodie</surname><given-names>L. E.</given-names></name><name><surname>Sattar</surname><given-names>N.</given-names></name></person-group><article-title>Obesity in pregnancy: prevalence and metabolic consequences</article-title><source><italic>Seminars in Fetal &#x00026; Neonatal Medicine</italic></source><year>2010</year><volume>15</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2009.09.006</pub-id><pub-id pub-id-type="pmid">19896913</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>G.</given-names></name><name><surname>Cseh</surname><given-names>K.</given-names></name><name><surname>Baranyi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Tumor necrosis factor system in insulin resistance in gestational diabetes</article-title><source><italic>Diabetes Research and Clinical Practice</italic></source><year>2002</year><volume>56</volume><fpage>93</fpage><lpage>99</lpage><?supplied-pmid 11891016?><pub-id pub-id-type="pmid">11891016</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molvarec</surname><given-names>A.</given-names></name><name><surname>Szarka</surname><given-names>A.</given-names></name><name><surname>Walentin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia</article-title><source><italic>Reproductive Biology and Endocrinology</italic></source><year>2011</year><volume>9</volume><fpage>p. 124</fpage><pub-id pub-id-type="doi">10.1186/1477-7827-9-124</pub-id><pub-id pub-id-type="other">2-s2.0-80052583870</pub-id><?supplied-pmid 21906313?><pub-id pub-id-type="pmid">21906313</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askari</surname><given-names>H.</given-names></name><name><surname>Tykodi</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Dagogo-Jack</surname><given-names>S.</given-names></name></person-group><article-title>Fasting plasma leptin level is a surrogate measure of insulin sensitivity</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2010</year><volume>95</volume><fpage>3836</fpage><lpage>3843</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0296</pub-id><pub-id pub-id-type="other">2-s2.0-77955385339</pub-id><?supplied-pmid 20484473?><pub-id pub-id-type="pmid">20484473</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouloumie</surname><given-names>A.</given-names></name><name><surname>Marumo</surname><given-names>T.</given-names></name><name><surname>Lafontan</surname><given-names>M.</given-names></name><name><surname>Busse</surname><given-names>R.</given-names></name></person-group><article-title>Leptin induces oxidative stress in human endothelial cells</article-title><source><italic>The FASEB Journal</italic></source><year>1999</year><volume>13</volume><fpage>1231</fpage><lpage>1238</lpage><?supplied-pmid 10385613?><pub-id pub-id-type="pmid">10385613</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautzky-Willer</surname><given-names>A.</given-names></name><name><surname>Pacini</surname><given-names>G.</given-names></name><name><surname>Tura</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Increased plasma leptin in gestational diabetes</article-title><source><italic>Diabetologia</italic></source><year>2001</year><volume>44</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/s001250051595</pub-id><pub-id pub-id-type="other">2-s2.0-0035131528</pub-id><?supplied-pmid 11270672?><pub-id pub-id-type="pmid">11270672</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>At&#x000e8;gbo</surname><given-names>J. M.</given-names></name><name><surname>Grissa</surname><given-names>O.</given-names></name><name><surname>Yessoufou</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Modulation of adipokines and cytokines in gestational diabetes and macrosomia</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2006</year><volume>91</volume><fpage>4137</fpage><lpage>4143</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-0980</pub-id><pub-id pub-id-type="other">2-s2.0-33749559832</pub-id><?supplied-pmid 16849405?><pub-id pub-id-type="pmid">16849405</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sibai</surname><given-names>B.</given-names></name><name><surname>Dekker</surname><given-names>G.</given-names></name><name><surname>Kupferminc</surname><given-names>M.</given-names></name></person-group><article-title>Pre-eclampsia</article-title><source><italic>Lancet (London, England)</italic></source><year>2005</year><volume>365</volume><fpage>785</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)17987-2</pub-id><pub-id pub-id-type="other">2-s2.0-14644412849</pub-id><?supplied-pmid 15733721?><pub-id pub-id-type="pmid">15733721</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tranquilli</surname><given-names>A. L.</given-names></name><name><surname>Brown</surname><given-names>M. A.</given-names></name><name><surname>Zeeman</surname><given-names>G. G.</given-names></name><name><surname>Dekker</surname><given-names>G.</given-names></name><name><surname>Sibai</surname><given-names>B. M.</given-names></name></person-group><article-title>The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP)</article-title><source><italic>Pregnancy Hypertens</italic></source><year>2013</year><volume>3</volume><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.preghy.2012.11.001</pub-id><pub-id pub-id-type="other">2-s2.0-84872351368</pub-id><?supplied-pmid 26105740?><pub-id pub-id-type="pmid">26105740</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><collab>American College of Obstetrics and Gynecology (ACOG)</collab><article-title>Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&#x02019; Task Force on Hypertension in Pregnancy</article-title><source><italic>Obstetrics and Gynecology</italic></source><year>2013</year><volume>122</volume><fpage>1122</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1097/01.AOG.0000437382.03963.8</pub-id><?supplied-pmid 24150027?><pub-id pub-id-type="pmid">24150027</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abhari</surname><given-names>F. R.</given-names></name><name><surname>Ghanbari Andarieh</surname><given-names>M.</given-names></name><name><surname>Farokhfar</surname><given-names>A.</given-names></name><name><surname>Ahmady</surname><given-names>S.</given-names></name></person-group><article-title>Estimating rate of insulin resistance in patients with preeclampsia using HOMA-IR index and comparison with nonpreeclampsia pregnant women</article-title><source><italic>BioMed Research International</italic></source><year>2014</year><volume>2014</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">140851</pub-id><pub-id pub-id-type="doi">10.1155/2014/140851</pub-id><pub-id pub-id-type="other">2-s2.0-84900022197</pub-id><?supplied-pmid 24812607?><pub-id pub-id-type="pmid">24812607</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scioscia</surname><given-names>M.</given-names></name><name><surname>Karumanchi</surname><given-names>S. A.</given-names></name><name><surname>Goldman-Wohl</surname><given-names>D.</given-names></name><name><surname>Robillard</surname><given-names>P. Y.</given-names></name></person-group><article-title>Endothelial dysfunction and metabolic syndrome in preeclampsia: an alternative viewpoint</article-title><source><italic>Journal of Reproductive Immunology</italic></source><year>2015</year><volume>108</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jri.2015.01.009</pub-id><pub-id pub-id-type="other">2-s2.0-84926247604</pub-id><?supplied-pmid 25766966?><pub-id pub-id-type="pmid">25766966</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>S.</given-names></name><name><surname>Mody</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Activation of villous trophoblastic p38 and ERK1/2 signaling pathways in preterm preeclampsia and HELLP syndrome</article-title><source><italic>Pathology Oncology Research</italic></source><year>2015</year><volume>21</volume><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1007/s12253-014-9872-9</pub-id><pub-id pub-id-type="other">2-s2.0-84939416015</pub-id><?supplied-pmid 25583406?><pub-id pub-id-type="pmid">25583406</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Serum soluble endoglin, plasma endothelin-1 and coagulation function in early onset severe preeclampsia with organ dysfunction</article-title><source><italic>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</italic></source><year>2010</year><volume>22</volume><fpage>371</fpage><lpage>374</lpage><?supplied-pmid 20594474?><pub-id pub-id-type="pmid">20594474</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaitu&#x02019;u-Lino</surname><given-names>T. J.</given-names></name><name><surname>Hastie</surname><given-names>R.</given-names></name><name><surname>Hannan</surname><given-names>N. J.</given-names></name><etal/></person-group><article-title>Loss of Akt increases soluble endoglin release from endothelial cells but not placenta</article-title><source><italic>Pregnancy Hypertens</italic></source><year>2016</year><volume>6</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.preghy.2016.02.002</pub-id><pub-id pub-id-type="other">2-s2.0-84965128144</pub-id><?supplied-pmid 27155335?><pub-id pub-id-type="pmid">27155335</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>N. L.</given-names></name><name><surname>Chiang</surname><given-names>S. H.</given-names></name><name><surname>Hsueh</surname><given-names>C. H.</given-names></name><name><surname>Liang</surname><given-names>Y. J.</given-names></name><name><surname>Chen</surname><given-names>Y. J.</given-names></name><name><surname>Lai</surname><given-names>L. P.</given-names></name></person-group><article-title>Metformin inhibits TNF-&#x003b1;-induced I&#x003ba;B kinase phosphorylation, I&#x003ba;B-&#x003b1; degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation</article-title><source><italic>International Journal of Cardiology</italic></source><year>2009</year><volume>134</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2008.04.010</pub-id><pub-id pub-id-type="other">2-s2.0-64849117472</pub-id><?supplied-pmid 18597869?><pub-id pub-id-type="pmid">18597869</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cudmore</surname><given-names>M. J.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Sissaoui</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1</article-title><source><italic>European Heart Journal</italic></source><year>2012</year><volume>33</volume><fpage>1150</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr065</pub-id><pub-id pub-id-type="other">2-s2.0-81855193460</pub-id><?supplied-pmid 21411816?><pub-id pub-id-type="pmid">21411816</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaamash</surname><given-names>A. H.</given-names></name><name><surname>Elsnosy</surname><given-names>E. D.</given-names></name><name><surname>Makhlouf</surname><given-names>A. M.</given-names></name><name><surname>Zakhari</surname><given-names>M. M.</given-names></name><name><surname>Ibrahim</surname><given-names>O. A.</given-names></name><name><surname>HM</surname><given-names>E L.-d.</given-names></name></person-group><article-title>Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia</article-title><source><italic>International Journal of Gynaecology and Obstetrics</italic></source><year>2000</year><volume>68</volume><fpage>207</fpage><lpage>214</lpage><?supplied-pmid 10699190?><pub-id pub-id-type="pmid">10699190</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demircan Sezer</surname><given-names>S.</given-names></name><name><surname>K&#x000fc;&#x000e7;&#x000fc;k</surname><given-names>M.</given-names></name><name><surname>Nergiz Avc&#x00131;o&#x0011f;lu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Comparison of maternal and umbilical cord blood HIF-1<italic>&#x003b1;</italic> and nitric oxide levels in early and late onset preeclamptic pregnancies</article-title><source><italic>Gynecological Endocrinology</italic></source><year>2015</year><volume>31</volume><fpage>945</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.3109/09513590.2015.1065483</pub-id><pub-id pub-id-type="other">2-s2.0-84949804609</pub-id><?supplied-pmid 26172929?><pub-id pub-id-type="pmid">26172929</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Garrido Chem</surname><given-names>J. A.</given-names></name><name><surname>Olivares-Corichi</surname><given-names>I. M.</given-names></name><name><surname>Tovar-Rodriguez</surname><given-names>J. M.</given-names></name><etal/></person-group><article-title>Influence of the AT(2) receptor on the L-arginine-nitric oxide pathway and effects of (-)-epicatechin on HUVECs from women with preeclampsia</article-title><source><italic>Journal of Human Hypertension</italic></source><year>2013</year><volume>27</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/jhh.2012.55</pub-id><pub-id pub-id-type="other">2-s2.0-84877589240</pub-id><?supplied-pmid 23223087?><pub-id pub-id-type="pmid">23223087</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scioscia</surname><given-names>M.</given-names></name><name><surname>Gumaa</surname><given-names>K.</given-names></name><name><surname>Kunjara</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2006</year><volume>91</volume><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-1965</pub-id><pub-id pub-id-type="other">2-s2.0-32544441869</pub-id><?supplied-pmid 16332940?><pub-id pub-id-type="pmid">16332940</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>S. E.</given-names></name><name><surname>Karumanchi</surname><given-names>S. A.</given-names></name></person-group><article-title>Angiogenic factors and preeclampsia</article-title><source><italic>Seminars in Nephrology</italic></source><year>2011</year><volume>31</volume><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.semnephrol.2010.10.004</pub-id><pub-id pub-id-type="other">2-s2.0-78751682439</pub-id><?supplied-pmid 21266263?><pub-id pub-id-type="pmid">21266263</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>S.</given-names></name><name><surname>Karumanchi</surname><given-names>S. A.</given-names></name><name><surname>Lindheimer</surname><given-names>M. D.</given-names></name></person-group><article-title>Angiogenic factors in diagnosis, management, and research in preeclampsia</article-title><source><italic>Hypertension</italic></source><year>2014</year><volume>63</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.113.02293</pub-id><pub-id pub-id-type="other">2-s2.0-84892925057</pub-id><?supplied-pmid 24166749?><pub-id pub-id-type="pmid">24166749</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdonk</surname><given-names>K.</given-names></name><name><surname>Saleh</surname><given-names>L.</given-names></name><name><surname>Lankhorst</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression</article-title><source><italic>Hypertension</italic></source><year>2015</year><volume>65</volume><fpage>1316</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.05267</pub-id><pub-id pub-id-type="other">2-s2.0-84937545842</pub-id><?supplied-pmid 25870197?><pub-id pub-id-type="pmid">25870197</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cindrova-Davies</surname><given-names>T.</given-names></name><name><surname>Sanders</surname><given-names>D. A.</given-names></name><name><surname>Burton</surname><given-names>G. J.</given-names></name><name><surname>Charnock-Jones</surname><given-names>D. S.</given-names></name></person-group><article-title>Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling</article-title><source><italic>Cardiovascular Research</italic></source><year>2011</year><volume>89</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq346</pub-id><pub-id pub-id-type="other">2-s2.0-79551485714</pub-id><?supplied-pmid 21139021?><pub-id pub-id-type="pmid">21139021</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuevas</surname><given-names>B. D.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Mao</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><fpage>27455</fpage><lpage>27461</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100556200</pub-id><pub-id pub-id-type="other">2-s2.0-0035920129</pub-id><?supplied-pmid 11337495?><pub-id pub-id-type="pmid">11337495</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orcy</surname><given-names>R. B.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Hofmeister Martins-Costa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Signalization of Akt/PKB in the placenta, skeletal muscle and adipose tissue of preeclampsia patients</article-title><source><italic>Gynecologic and Obstetric Investigation</italic></source><year>2008</year><volume>66</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1159/000147169</pub-id><pub-id pub-id-type="other">2-s2.0-47549089946</pub-id><?supplied-pmid 18645256?><pub-id pub-id-type="pmid">18645256</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S. Y.</given-names></name><name><surname>Callaghan</surname><given-names>W. M.</given-names></name><name><surname>Kim</surname><given-names>S. Y.</given-names></name><etal/></person-group><article-title>Maternal obesity and risk of gestational diabetes mellitus</article-title><source><italic>Diabetes Care</italic></source><year>2007</year><volume>30</volume><fpage>2070</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.2337/dc06-2559a</pub-id><pub-id pub-id-type="other">2-s2.0-34547662414</pub-id><?supplied-pmid 17416786?><pub-id pub-id-type="pmid">17416786</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellamy</surname><given-names>L.</given-names></name><name><surname>Casas</surname><given-names>J.-P.</given-names></name><name><surname>Hingorani</surname><given-names>A. D.</given-names></name><name><surname>Williams</surname><given-names>D.</given-names></name></person-group><article-title>Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis</article-title><source><italic>Lancet</italic></source><year>2009</year><volume>373</volume><fpage>1773</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60731-5</pub-id><pub-id pub-id-type="other">2-s2.0-65649084159</pub-id><?supplied-pmid 19465232?><pub-id pub-id-type="pmid">19465232</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalano</surname><given-names>P. M.</given-names></name><name><surname>Tyzbir</surname><given-names>E. D.</given-names></name><name><surname>Wolfe</surname><given-names>R. R.</given-names></name><etal/></person-group><article-title>Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes</article-title><source><italic>The American Journal of Physiology</italic></source><year>1993</year><volume>264</volume><fpage>E60</fpage><lpage>E67</lpage><?supplied-pmid 8430789?><pub-id pub-id-type="pmid">8430789</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>B. L.</given-names></name><name><surname>Metzger</surname><given-names>B. E.</given-names></name><name><surname>Cho</surname><given-names>N. H.</given-names></name><name><surname>Loeb</surname><given-names>C. A.</given-names></name></person-group><article-title>Impaired glucose tolerance in adolescent offspring of diabetic mothers: relationship to fetal hyperinsulinism</article-title><source><italic>Diabetes Care</italic></source><year>1995</year><volume>18</volume><fpage>611</fpage><lpage>617</lpage><?supplied-pmid 8585997?><pub-id pub-id-type="pmid">8585997</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanhal</surname><given-names>C. Y.</given-names></name><name><surname>Daglar</surname><given-names>H. K.</given-names></name><name><surname>Kara</surname><given-names>O.</given-names></name><name><surname>Uygur</surname><given-names>D.</given-names></name><name><surname>Yucel</surname><given-names>A.</given-names></name></person-group><article-title>Assessment of fetal myocardial performance index in women with pregestational and gestational diabetes mellitus</article-title><source><italic>The Journal of Obstetrics and Gynaecology Research</italic></source><year>2017</year><volume>43</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/jog.13174</pub-id><pub-id pub-id-type="other">2-s2.0-85003475065</pub-id><?supplied-pmid 27862741?><pub-id pub-id-type="pmid">27862741</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheffield</surname><given-names>J. S.</given-names></name><name><surname>Butler-Koster</surname><given-names>E. L.</given-names></name><name><surname>Casey</surname><given-names>B. M.</given-names></name><name><surname>DD</surname><given-names>M. I.</given-names></name><name><surname>Leveno</surname><given-names>K. J.</given-names></name></person-group><article-title>Maternal diabetes mellitus and infant malformations</article-title><source><italic>Obstetrics and Gynecology</italic></source><year>2002</year><volume>100</volume><fpage>925</fpage><lpage>930</lpage><?supplied-pmid 12423854?><pub-id pub-id-type="pmid">12423854</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nold</surname><given-names>J. L.</given-names></name><name><surname>Georgieff</surname><given-names>M. K.</given-names></name></person-group><article-title>Infants of diabetic mothers</article-title><source><italic>Pediatric Clinics of North America</italic></source><year>2004</year><volume>51</volume><fpage>619</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.pcl.2004.01.003</pub-id><pub-id pub-id-type="other">2-s2.0-2442530562</pub-id><?supplied-pmid 15157588?><pub-id pub-id-type="pmid">15157588</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitanchez</surname><given-names>D.</given-names></name><name><surname>Burguet</surname><given-names>A.</given-names></name><name><surname>Simeoni</surname><given-names>U.</given-names></name></person-group><article-title>Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health</article-title><source><italic>The Journal of Pediatrics</italic></source><year>2014</year><volume>164</volume><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2013.10.076</pub-id><pub-id pub-id-type="other">2-s2.0-84894344033</pub-id><?supplied-pmid 24331686?><pub-id pub-id-type="pmid">24331686</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermeier</surname><given-names>F.</given-names></name><name><surname>Salom&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Far&#x000ed;as</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Insulin requires normal expression and signaling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium</article-title><source><italic>The FASEB Journal</italic></source><year>2015</year><volume>29</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1096/fj.14-254219</pub-id><pub-id pub-id-type="other">2-s2.0-84923544570</pub-id><?supplied-pmid 25351985?><pub-id pub-id-type="pmid">25351985</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleli</surname><given-names>M.</given-names></name><name><surname>Fredholm</surname><given-names>B.</given-names></name><name><surname>Sobrevia</surname><given-names>L.</given-names></name><name><surname>Carlstr&#x000f6;m</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacological targeting of adenosine receptor signalling</article-title><source><italic>Molecular Aspects of Medicine</italic></source><year>2017</year><volume>55</volume><fpage>4</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2016.12.002</pub-id><pub-id pub-id-type="pmid">28088486</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzm&#x000e1;n-Guti&#x000e9;rrez</surname><given-names>E.</given-names></name><name><surname>Armella</surname><given-names>A.</given-names></name><name><surname>Toledo</surname><given-names>F.</given-names></name><name><surname>Pardo</surname><given-names>F.</given-names></name><name><surname>Leiva</surname><given-names>A.</given-names></name><name><surname>Sobrevia</surname><given-names>L.</given-names></name></person-group><article-title>Insulin requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-arginine transport in human umbilical vein endothelium</article-title><source><italic>Purinergic Signal</italic></source><year>2016</year><volume>12</volume><fpage>175</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1007/s11302-015-9491-2</pub-id><pub-id pub-id-type="other">2-s2.0-84957967496</pub-id><?supplied-pmid 26710791?><pub-id pub-id-type="pmid">26710791</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>A.</given-names></name><name><surname>Maymo</surname><given-names>J. L.</given-names></name><name><surname>Gambino</surname><given-names>Y. P.</given-names></name><etal/></person-group><article-title>Activated translation signaling in placenta from pregnant women with gestational diabetes mellitus: possible role of leptin</article-title><source><italic>Hormone and Metabolic Research</italic></source><year>2013a</year><volume>45</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1333276</pub-id><pub-id pub-id-type="other">2-s2.0-84878582344</pub-id><?supplied-pmid 23386416?><pub-id pub-id-type="pmid">23386416</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>GDM-induced macrosomia is reversed by Cav-1 via AMPK-mediated fatty acid transport and GLUT1-mediated glucose transport in placenta</article-title><source><italic>PLoS One</italic></source><year>2017</year><volume>12</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0170490</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>M. T.</given-names></name><name><surname>Oliva</surname><given-names>K.</given-names></name><name><surname>Georgiou</surname><given-names>H. M.</given-names></name><name><surname>Permezel</surname><given-names>J. M.</given-names></name><name><surname>Rice</surname><given-names>G. E.</given-names></name></person-group><article-title>Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus</article-title><source><italic>Diabetic Medicine</italic></source><year>2001</year><volume>18</volume><fpage>921</fpage><lpage>927</lpage><?supplied-pmid 11703438?><pub-id pub-id-type="pmid">11703438</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>M. T.</given-names></name><name><surname>Permezel</surname><given-names>M.</given-names></name><name><surname>Georgiou</surname><given-names>H. M.</given-names></name><name><surname>Rice</surname><given-names>G. E.</given-names></name></person-group><article-title>Repression of oxidant-induced nuclear factor-&#x003ba;B activity mediates placental cytokine responses in gestational diabetes</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2004</year><volume>89</volume><fpage>3585</fpage><lpage>3594</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031953</pub-id><pub-id pub-id-type="other">2-s2.0-3242657864</pub-id><?supplied-pmid 15240650?><pub-id pub-id-type="pmid">15240650</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>A.</given-names></name><name><surname>Maym&#x000f3;</surname><given-names>J.</given-names></name><name><surname>Gambino</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Insulin enhances leptin expression in human trophoblastic cells</article-title><source><italic>Biology of Reproduction</italic></source><year>2013b</year><volume>89</volume><fpage>p. 20</fpage><pub-id pub-id-type="doi">10.1095/biolreprod.113.109348</pub-id><pub-id pub-id-type="other">2-s2.0-84889076184</pub-id><?supplied-pmid 23718986?><pub-id pub-id-type="pmid">23718986</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>J.</given-names></name><name><surname>Sebert</surname><given-names>S.</given-names></name><name><surname>Segura</surname><given-names>M. T.</given-names></name><etal/></person-group><article-title>Maternal body weight and gestational diabetes differentially influence placental and pregnancy outcomes</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2016</year><volume>101</volume><fpage>59</fpage><lpage>68</lpage><?supplied-pmid 26513002?><pub-id pub-id-type="pmid">26513002</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>R.</given-names></name><name><surname>Summers</surname><given-names>K.</given-names></name><name><surname>De Vrijer</surname><given-names>B.</given-names></name><name><surname>Cohen</surname><given-names>N.</given-names></name><name><surname>Thompson</surname><given-names>A.</given-names></name><name><surname>Giroux</surname><given-names>I.</given-names></name></person-group><article-title>Maternal, umbilical arterial and umbilical venous 25-hydroxyvitamin D and adipocytokine concentrations in pregnancies with and without gestational diabetes</article-title><source><italic>Clinical Endocrinology</italic></source><year>2014</year><volume>80</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1111/cen.12325</pub-id><pub-id pub-id-type="other">2-s2.0-84898549756</pub-id><?supplied-pmid 24102192?><pub-id pub-id-type="pmid">24102192</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colomiere</surname><given-names>M.</given-names></name><name><surname>Permezel</surname><given-names>M.</given-names></name><name><surname>Riley</surname><given-names>C.</given-names></name><name><surname>Desoye</surname><given-names>G.</given-names></name><name><surname>Lappas</surname><given-names>M.</given-names></name></person-group><article-title>Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus</article-title><source><italic>European Journal of Endocrinology</italic></source><year>2009</year><volume>160</volume><fpage>567</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1530/EJE-09-0031</pub-id><pub-id pub-id-type="other">2-s2.0-64549160282</pub-id><?supplied-pmid 19179458?><pub-id pub-id-type="pmid">19179458</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subiabre</surname><given-names>M.</given-names></name><name><surname>Silva</surname><given-names>L.</given-names></name><name><surname>Villalobos-Labra</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Maternal insulin therapy does not restore foetoplacental endothelial dysfunction in gestational diabetes mellitus</article-title><source><italic>Biochimica et Biophysica Acta Molecular Basis of Disease</italic></source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.bbadis.2017.07.022</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koning</surname><given-names>S. H.</given-names></name><name><surname>Hoogenberg</surname><given-names>K.</given-names></name><name><surname>Scheuneman</surname><given-names>K. A.</given-names></name><etal/></person-group><article-title>Neonatal and obstetric outcomes in diet- and insulin-treated women with gestational diabetes mellitus: a retrospective study</article-title><source><italic>BMC Endocrine Disorders</italic></source><year>2016</year><volume>16</volume><fpage>p. 52</fpage><pub-id pub-id-type="doi">10.1186/s12902-016-0136-4</pub-id><pub-id pub-id-type="other">2-s2.0-84988958030</pub-id><?supplied-pmid 27680327?><pub-id pub-id-type="pmid">27680327</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>R. T.</given-names></name><name><surname>Glastras</surname><given-names>S. J.</given-names></name><name><surname>Hocking</surname><given-names>S.</given-names></name><name><surname>Fulcher</surname><given-names>G. R.</given-names></name></person-group><article-title>Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes</article-title><source><italic>Diabetes Research and Clinical Practice</italic></source><year>2016</year><volume>116</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2016.04.051</pub-id><pub-id pub-id-type="other">2-s2.0-84964921004</pub-id><?supplied-pmid 27321322?><pub-id pub-id-type="pmid">27321322</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>B.</given-names></name><name><surname>Stangenberg</surname><given-names>M.</given-names></name><name><surname>Hansson</surname><given-names>U.</given-names></name><name><surname>Nordlander</surname><given-names>E.</given-names></name></person-group><article-title>Gestational diabetes mellitus (GDM). Comparative evaluation of two treatment regimens, diet versus insulin and diet</article-title><source><italic>Diabetes</italic></source><year>1985</year><volume>34</volume><fpage>101</fpage><lpage>105</lpage><?supplied-pmid 3888734?><pub-id pub-id-type="pmid">3888734</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verier-Mine</surname><given-names>O.</given-names></name></person-group><article-title>Outcomes in women with a history of gestational diabetes. Screening and prevention of type 2 diabetes. Literature review</article-title><source><italic>Diabetes &#x00026; Metabolism</italic></source><year>2010</year><volume>36</volume><fpage>595</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.diabet.2010.11.011</pub-id><?supplied-pmid 21163424?><pub-id pub-id-type="pmid">21163424</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>S. M.</given-names></name><name><surname>Brewer</surname><given-names>H. B.</given-names></name><name><surname>Cleeman</surname><given-names>J. I.</given-names></name><name><surname>Smith</surname><given-names>S. C.</given-names><suffix>Jr.</suffix></name><name><surname>Lenfant</surname><given-names>C.</given-names></name><name><surname>American Heart Association, National Heart, Lung, and Blood Institute</surname></name></person-group><article-title>Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American Heart Association Conference on Scientific Issues Related to Definition</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000111245.75752.C6</pub-id><pub-id pub-id-type="other">2-s2.0-0842277242</pub-id><?supplied-pmid 14744958?><pub-id pub-id-type="pmid">14744958</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalano</surname><given-names>P. M.</given-names></name><name><surname>Presley</surname><given-names>L.</given-names></name><name><surname>Minium</surname><given-names>J.</given-names></name><name><surname>Hauguel-de Mouzon</surname><given-names>S.</given-names></name></person-group><article-title>Fetuses of obese mothers develop insulin resistance in utero</article-title><source><italic>Diabetes Care</italic></source><year>2009</year><volume>32</volume><fpage>1076</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.2337/dc08-2077</pub-id><pub-id pub-id-type="other">2-s2.0-66549089201</pub-id><?supplied-pmid 19460915?><pub-id pub-id-type="pmid">19460915</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simental-Mend&#x000ed;a</surname><given-names>L. E.</given-names></name><name><surname>Casta&#x000f1;eda-Chac&#x000f3;n</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez-Mor&#x000e1;n</surname><given-names>M.</given-names></name><name><surname>Guerrero-Romero</surname><given-names>F.</given-names></name></person-group><article-title>Birth-weight, insulin levels, and HOMA-IR in newborns at term</article-title><source><italic>BMC Pediatrics</italic></source><year>2012</year><volume>12</volume><fpage>p. 94</fpage><pub-id pub-id-type="doi">10.1186/1471-2431-12-94</pub-id><pub-id pub-id-type="other">2-s2.0-84863486581</pub-id><?supplied-pmid 22770114?><pub-id pub-id-type="pmid">22770114</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirkola</surname><given-names>J.</given-names></name><name><surname>Pouta</surname><given-names>A.</given-names></name><name><surname>Bloigu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Risks of overweight and abdominal obesity at age 16 years associated with prenatal exposures to maternal prepregnancy overweight and gestational diabetes mellitus</article-title><source><italic>Diabetes Care</italic></source><year>2010</year><volume>33</volume><fpage>1115</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.2337/dc09-1871</pub-id><pub-id pub-id-type="other">2-s2.0-77954937547</pub-id><?supplied-pmid 20427685?><pub-id pub-id-type="pmid">20427685</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaillard</surname><given-names>R.</given-names></name><name><surname>Steegers</surname><given-names>E. A. P.</given-names></name><name><surname>Duijts</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Childhood cardiometabolic outcomes of maternal obesity during pregnancy: the generation R study</article-title><source><italic>Hypertension</italic></source><year>2014</year><volume>63</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.113.02671</pub-id><pub-id pub-id-type="other">2-s2.0-84897036831</pub-id><?supplied-pmid 24379180?><pub-id pub-id-type="pmid">24379180</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakali</surname><given-names>K. M.</given-names></name><name><surname>Saben</surname><given-names>J.</given-names></name><name><surname>Faske</surname><given-names>J. B.</given-names></name><etal/></person-group><article-title>Maternal pregravid obesity changes gene expression profiles toward greater inflammation and reduced insulin sensitivity in umbilical cord</article-title><source><italic>Pediatric Research</italic></source><year>2014</year><volume>76</volume><fpage>202</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/pr.2014.72</pub-id><pub-id pub-id-type="other">2-s2.0-84904611580</pub-id><?supplied-pmid 24819376?><pub-id pub-id-type="pmid">24819376</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saben</surname><given-names>J.</given-names></name><name><surname>Lindsey</surname><given-names>F.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Maternal obesity is associated with a lipotoxic placental environment</article-title><source><italic>Placenta</italic></source><year>2014</year><volume>35</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2014.01.003</pub-id><pub-id pub-id-type="other">2-s2.0-84894459066</pub-id><?supplied-pmid 24484739?><pub-id pub-id-type="pmid">24484739</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>N.</given-names></name><name><surname>Rosario</surname><given-names>F. J.</given-names></name><name><surname>Gaccioli</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>2013</year><volume>98</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-2667</pub-id><pub-id pub-id-type="other">2-s2.0-84872068779</pub-id><?supplied-pmid 23150676?><pub-id pub-id-type="pmid">23150676</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>N.</given-names></name><name><surname>Nilsfelt</surname><given-names>A.</given-names></name><name><surname>Gellerstedt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Maternal hormones linking maternal body mass index and dietary intake to birth weight</article-title><source><italic>The American Journal of Clinical Nutrition</italic></source><year>2008</year><volume>87</volume><fpage>1743</fpage><lpage>1749</lpage><?supplied-pmid 18541564?><pub-id pub-id-type="pmid">18541564</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saben</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Gomez-Acevedo</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity</article-title><source><italic>The American Journal of Physiology</italic></source><year>2013</year><volume>305</volume><fpage>E1</fpage><lpage>E14</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00076.2013</pub-id><pub-id pub-id-type="other">2-s2.0-84879595431</pub-id><?supplied-pmid 23632636?><pub-id pub-id-type="pmid">23632636</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par&#x000e9;</surname><given-names>E.</given-names></name><name><surname>Parry</surname><given-names>S.</given-names></name><name><surname>McElrath</surname><given-names>T. F.</given-names></name><name><surname>Pucci</surname><given-names>D.</given-names></name><name><surname>Newton</surname><given-names>A.</given-names></name><name><surname>Lim</surname><given-names>K. H.</given-names></name></person-group><article-title>Clinical risk factors for preeclampsia in the 21st century</article-title><source><italic>Obstetrics and Gynecology</italic></source><year>2014</year><volume>124</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000000451</pub-id><pub-id pub-id-type="other">2-s2.0-84915813310</pub-id><?supplied-pmid 25198274?><pub-id pub-id-type="pmid">25198274</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>T.-H.</given-names></name><name><surname>Hsieh</surname><given-names>T.-T.</given-names></name></person-group><article-title>Pregestational body mass index, gestational weight gain, and risks for adverse pregnancy outcomes among Taiwanese women: a retrospective cohort study</article-title><source><italic>Taiwanese Journal of Obstetrics &#x00026; Gynecology</italic></source><year>2016</year><volume>55</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.tjog.2016.06.016</pub-id><pub-id pub-id-type="other">2-s2.0-84992724167</pub-id><?supplied-pmid 27590385?><pub-id pub-id-type="pmid">27590385</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieber-Rotheneder</surname><given-names>M.</given-names></name><name><surname>Beganovic</surname><given-names>S.</given-names></name><name><surname>Desoye</surname><given-names>G.</given-names></name><name><surname>Lang</surname><given-names>U.</given-names></name><name><surname>Cervar-Zivkovic</surname><given-names>M.</given-names></name></person-group><article-title>Complex expression changes of the placental endothelin system in early and late onset preeclampsia, fetal growth restriction and gestational diabetes</article-title><source><italic>Life Sciences</italic></source><year>2012</year><volume>91</volume><fpage>710</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2012.04.040</pub-id><pub-id pub-id-type="other">2-s2.0-84867573173</pub-id><?supplied-pmid 22580289?><pub-id pub-id-type="pmid">22580289</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name></person-group><article-title>Expression of endothelial nitric oxide synthase traffic inducer in the placentas of women with pre-eclampsia</article-title><source><italic>International Journal of Gynaecology and Obstetrics</italic></source><year>2005</year><volume>89</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2004.12.041</pub-id><pub-id pub-id-type="other">2-s2.0-17844403977</pub-id><?supplied-pmid 15847871?><pub-id pub-id-type="pmid">15847871</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>G. D.</given-names></name><name><surname>Orcy</surname><given-names>R. B.</given-names></name><name><surname>Martins-Costa</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title>Insulin stimulation of Akt/PKB phosphorylation in the placenta of preeclampsia patients</article-title><source><italic>S&#x000e3;o Paulo Medical Journal</italic></source><year>2011</year><volume>129</volume><fpage>387</fpage><lpage>391</lpage><?supplied-pmid 22249794?><pub-id pub-id-type="pmid">22249794</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>C.</given-names></name><name><surname>Bertoglia</surname><given-names>P.</given-names></name><name><surname>Hernadez</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impaired A2A adenosine receptor/nitric oxide/VEGF signaling pathway in fetal endothelium during late- and early-onset preeclampsia</article-title><source><italic>Purinergic Signal</italic></source><year>2013</year><volume>9</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s11302-012-9341-4</pub-id><pub-id pub-id-type="other">2-s2.0-84877607150</pub-id><?supplied-pmid 23179048?><pub-id pub-id-type="pmid">23179048</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Athayde</surname><given-names>N.</given-names></name><name><surname>Trudinger</surname><given-names>B.</given-names></name></person-group><article-title>Maternal plasma from pregnant women with umbilical placental vascular disease does not affect endothelial cell mRNA expression of nitric oxide synthase</article-title><source><italic>Journal of the Society for Gynecologic Investigation</italic></source><year>2004</year><volume>11</volume><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.jsgi.2003.10.004</pub-id><pub-id pub-id-type="other">2-s2.0-1642487319</pub-id><?supplied-pmid 15051034?><pub-id pub-id-type="pmid">15051034</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Gonz&#x000e1;lez Del Rey</surname><given-names>C.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Tolivia</surname><given-names>J.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>C. G.</given-names></name></person-group><article-title>Effects of gestational diabetes mellitus on proteins implicated in insulin signaling in human placenta</article-title><source><italic>Gynecological Endocrinology</italic></source><year>2006</year><volume>22</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1080/09513590600921374</pub-id><pub-id pub-id-type="other">2-s2.0-33750478017</pub-id><?supplied-pmid 17071539?><pub-id pub-id-type="pmid">17071539</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sati</surname><given-names>L.</given-names></name><name><surname>Soygur</surname><given-names>B.</given-names></name><name><surname>Celik-Ozenci</surname><given-names>C.</given-names></name></person-group><article-title>Expression of mammalian target of rapamycin and downstream targets in normal and gestational diabetic human term placenta</article-title><source><italic>Reproductive Sciences</italic></source><year>2016</year><volume>23</volume><fpage>324</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1177/1933719115602765</pub-id><pub-id pub-id-type="other">2-s2.0-84957953956</pub-id><?supplied-pmid 26335179?><pub-id pub-id-type="pmid">26335179</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Adiponectin exerts antiproliferative effect on human placenta via modulation of the JNK/c-jun pathway</article-title><source><italic>International Journal of Clinical and Experimental Pathology</italic></source><year>2014</year><volume>7</volume><fpage>2894</fpage><lpage>2904</lpage><?supplied-pmid 25031708?><pub-id pub-id-type="pmid">25031708</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marseille-Tremblay</surname><given-names>C.</given-names></name><name><surname>Ethier-Chiasson</surname><given-names>M.</given-names></name><name><surname>Forest</surname><given-names>J.-C.</given-names></name><etal/></person-group><article-title>Impact of maternal circulating cholesterol and gestational diabetes mellitus on lipid metabolism in human term placenta</article-title><source><italic>Molecular Reproduction and Development</italic></source><year>2008</year><volume>75</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1002/mrd.20842</pub-id><pub-id pub-id-type="other">2-s2.0-42949122028</pub-id><?supplied-pmid 18095312?><pub-id pub-id-type="pmid">18095312</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subiabre</surname><given-names>M.</given-names></name><name><surname>Salsoso</surname><given-names>R.</given-names></name><name><surname>Villalobos-Labra</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Insulin therapy fails to reverse the human foetoplacental endothelial dysfunction in gestational diabetes mellitus</article-title><source><italic>Placenta</italic></source><year>2017</year><volume>51</volume><fpage>117</fpage><lpage>118</lpage></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salom&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Westermeier</surname><given-names>F.</given-names></name><name><surname>Puebla</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Gestational diabetes reduces adenosine transport in human placental microvascular endothelium, an effect reversed by insulin</article-title><source><italic>PLoS One</italic></source><year>2012</year><volume>7, article e40578</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0040578</pub-id><pub-id pub-id-type="other">2-s2.0-84863733127</pub-id><?supplied-pmid 22808198?><pub-id pub-id-type="pmid">22808198</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brett</surname><given-names>K. E.</given-names></name><name><surname>Ferraro</surname><given-names>Z. M.</given-names></name><name><surname>Holcik</surname><given-names>M.</given-names></name><name><surname>Adamo</surname><given-names>K. B.</given-names></name></person-group><article-title>Placenta nutrient transport-related gene expression: the impact of maternal obesity and excessive gestational weight gain</article-title><source><italic>The Journal of Maternal-Fetal &#x00026; Neonatal Medicine</italic></source><year>2016</year><volume>29</volume><fpage>1399</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.3109/14767058.2015.1049522</pub-id><pub-id pub-id-type="other">2-s2.0-84958157801</pub-id><?supplied-pmid 26067267?><pub-id pub-id-type="pmid">26067267</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Insulin signalling in the human feotoplacental vasculature. Insulin activates insulin receptors A (IR-A) and B (IR-B) leading to recruitment and activation of insulin receptor substrates 1 and 2 (IRS1/2) and Src homology 2 domain-containing transforming protein 1 type A of 42 and 56&#x02009;kDa (SHcA42/56). IR-A activation causes preferential activation of SHcA42/56, which triggers signalling through the growth factor receptor-bound protein 2 (Grb2) cascade ending in higher (&#x021e7;) activity of the 44 and 42&#x02009;kDa mitogen-protein kinases (p44/42<sup>mapk</sup>). IR-B activation causes preferential activation of IRS1/2, which triggers signalling through the phosphatidylinositol 3 kinase (PI3K) cascade ending in higher protein kinase B/Akt (Akt) activity. IR-A signalling and IR-B signalling increase the endothelial nitric oxide (NO) synthase (eNOS) activity to generate nitric oxide (NO). An increase in the NO synthesis results in relaxation of the foetoplacental vascular beds (<italic>vasodilation</italic>).</p></caption><graphic xlink:href="JDR2017-5947859.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cell signalling in insulin resistance in the human foetoplacental vasculature. Insulin activates insulin receptors A (IR-A) and B (IR-B) leading to recruitment and activation of insulin receptor substrates 1 and 2 (IRS1/2) and Src homology 2 domain-containing transforming protein 1 type A of 42 and 56&#x02009;kDa (SHcA42/56). IR-A activation causes preferential activation of SHcA42/56, which triggers signalling through the growth factor receptor-bound protein 2 (Grb2) ending in increased (&#x021e7;) activity of the 44 and 42&#x02009;kDa mitogen-protein kinases (p44/42<sup>mapk</sup>) and c-Jun N-terminal kinases (JNK). IR-B activation causes preferential activation of IRS<sup>1/2</sup> triggering signalling by the p85<italic>&#x003b1;</italic> regulatory subunit of phosphatidylinositol 3 kinase (PI3K p85<italic>&#x003b1;</italic>). Activation of this subunit of PI3K decreases (&#x021e9;) the protein kinase B/Akt (Akt) activity ending in reduced endothelial nitric oxide (NO) synthase (eNOS) activity and NO generation. Reduced Akt activity also results in lower activity of the mammalian target of rapamycin (mTOR) activity, which turns into reduced activity of the adenosine monophosphate protein kinase (AMPK). Reduced AMPK activity is also caused by the reduced plasma level of adiponectin (an AMPK-activator) thus releasing AMPK-inhibition of mTOR facilitating activation of this molecule. This phenomenon potentially (?) increases mTOR-activated signalling through p70 S6 kinase 1 (S6&#x02009;K1) thus reducing IRS1/2 signalling. The increased extracellular level of leptin and tumour necrosis factor <italic>&#x003b1;</italic> (TNF<italic>&#x003b1;</italic>) results in JNK activation. The possibility that JNK increases the inhibitor phosphorylation of IRS1/2 (Ser<sup>312</sup>) reducing insulin signalling (?) is likely. All in concert, these mechanisms lead to a state of lower response to insulin of the human foetoplacental vasculature (<italic>insulin resistance</italic>). Blue arrows denote activation. Red arrows denote inhibition.</p></caption><graphic xlink:href="JDR2017-5947859.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Potential involvement of Akt/mTOR in insulin resistance in the human foetoplacental unit from diseases of pregnancy. Pregestational maternal obesity (PGMO), gestational diabetes mellitus (GDM), and preeclampsia are diseases of pregnancy where the human foetoplacental endothelial function is reduced. The response of the placenta to insulin results from activation of insulin receptor A (IR-A) via preferential signalling through Src homology 2 domain-containing transforming protein 1 type A (IR-A/SHcA) and insulin receptor B (IR-B) via preferential signalling through insulin receptor substrates (IR-B/IRSs). The effect of PGMO (represented as orange bars), GDM (represented as green bars), and PE (represented as blue bars) in the cell signalling triggered by insulin causes an increase (+) or a decrease (&#x02212;) in the expression and activity of the indicated associated signalling molecules for each pathology. The defective action of insulin is also documented for a reduced (&#x021e9;) activity of protein kinase B/Akt (Akt) due to signalling molecules that are reported for PGMO and early onset PE (<italic>EOPE</italic>), a phenomenon that is less clear (?) in GDM pregnancies. Reduced Akt activity results in reduced expression and activity of the mammalian target of rapamycin (mTOR) and its signalling in cells from PGMO, with a not clear mechanism (?) in GDM and PE. These changes result in reduced activation of the endothelial nitric oxide (NO) synthase (eNOS) activity leading to lower NO generation in PGMO and EOPE but increased eNOS activity in GDM and late onset PE (LOPE). These mechanisms lead to a reduced Akt/mTOR signalling cascade in response to insulin (<italic>insulin resistance</italic>) in the foetoplacental vasculature. This condition's outcome is a reduced vasodilation with several other adverse foetal outcomes and higher risk of developing adulthood diseases. PI3K: phosphatidylinositol 3 kinase; AMPK: adenosine monophosphate kinase; SK61: p70 S6 kinase 1; TNF<italic>&#x003b1;</italic>: tumour necrosis factor <italic>&#x003b1;</italic>; PDK1: human 3-phosphoinositide-dependent protein kinase 1; JNK: c-Jun N-terminal kinases. Specific signalling mechanisms for each molecule shown are described in the text. The magnitude of the bars represents the degree of involvement of the diseases of pregnancy at the corresponding mechanism.</p></caption><graphic xlink:href="JDR2017-5947859.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Effect of pathologies of pregnancy on insulin signalling in the human foetoplacental vasculature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Cell or tissue</th><th align="center" rowspan="1" colspan="1">Molecule or activity</th><th align="center" rowspan="1" colspan="1">Effect of the pathology</th><th align="center" rowspan="1" colspan="1">Effect of insulin</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<italic>Preeclampsia</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (EOPE)</td><td align="center" rowspan="1" colspan="1">p44/42<sup>mapk</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B57" ref-type="bibr">57</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (EOPE)</td><td align="center" rowspan="1" colspan="1">ET-1, ET<sub>A</sub>, and ET<sub>B</sub> (mRNA)</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">Akt-Ser<sup>473</sup></td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">eNOS</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (LOPE)</td><td align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>-IR, IRS-1-Tyr<sup>465</sup>, IRS-1-Ser<sup>312</sup>, and IRS-2-Ser<sup>731</sup></td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (LOPE)</td><td align="center" rowspan="1" colspan="1">Akt-Ser<sup>473</sup></td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B110" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (LOPE)</td><td align="center" rowspan="1" colspan="1">eNOS-Thr<sup>495</sup>, eNOS-Ser<sup>1177</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B20" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (LOPE)</td><td align="center" rowspan="1" colspan="1">eNOS-Ser<sup>1177</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B111" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (EOPE)</td><td align="center" rowspan="1" colspan="1">eNOS</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B111" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">eNOS</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B112" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (LOPE)</td><td align="center" rowspan="1" colspan="1">L-Arginine transport</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B20" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (LOPE)<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">hCAT-1</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B20" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Gestational diabetes mellitus</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">IRs</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (insulin therapy)<sup>&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>-IR</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">IRS-1</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (insulin therapy)</td><td align="center" rowspan="1" colspan="1">IRS-1</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (insulin therapy)</td><td align="center" rowspan="1" colspan="1">IRS-2</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">PI3K p85<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">PI3K p85<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (insulin therapy)</td><td align="center" rowspan="1" colspan="1">PI3K p110</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta<sup>&#x02217;&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">mTOR-Ser<sup>2448</sup>, S6K1-Thr<sup>421</sup>/Ser<sup>424</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta<sup>&#x02217;&#x02217;&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">S6&#x02009;K1-Thr<sup>389</sup>, 4EBP1-Thr<sup>37/46</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B114" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta<sup>&#x02217;&#x02217;&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">4EBP1-Thr<sup>37/46</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">AMPK (mRNA)</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">Adiponectin</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B115" ref-type="bibr">115</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">TNF-<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B116" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta (insulin therapy)</td><td align="center" rowspan="1" colspan="1">TNF-<italic>&#x003b1;</italic></td><td align="center" rowspan="1" colspan="1">Unaltered</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B86" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">IL-1<italic>&#x003b2;</italic></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B116" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">Leptin receptor</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Trophoblast</td><td align="center" rowspan="1" colspan="1">Leptin receptor</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B87" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">IR-A (mRNA)</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B21" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">Akt-Ser<sup>473</sup></td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">eNOS, eNOS-Ser<sup>1177</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">p44/42<sup>mapk</sup>-Thr<sup>202/204</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (insulin therapy)</td><td align="center" rowspan="1" colspan="1">eNOS, eNOS-Ser<sup>1177</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">hENT1, adenosine transport</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">[<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs</td><td align="center" rowspan="1" colspan="1">L-Arginine transport</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HUVECs (insulin therapy)</td><td align="center" rowspan="1" colspan="1">L-Arginine transport</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">p44/42<sup>mapk</sup>-Thr<sup>202/204</sup>, Akt-Ser<sup>473</sup></td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">IR-A (mRNA)</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">IR-B (mRNA)</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">hENT1</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">hENT2</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">hENT1 transport activity</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">No effect</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">hPMECs</td><td align="center" rowspan="1" colspan="1">hENT2 transport activity</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">Restored</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Umbilical cord plasma</td><td align="center" rowspan="1" colspan="1">Leptin</td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Umbilical cord plasma</td><td align="center" rowspan="1" colspan="1">Adiponectin</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B89" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Pregestational maternal obesity</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">AMPK-Thr<sup>172</sup></td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">AMPK</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">S6&#x02009;K1-Thr<sup>389</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B119" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">JNK-Thr<sup>183</sup>/Tyr<sup>185</sup></td><td align="center" rowspan="1" colspan="1">Increase</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B119" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">mTOR (mRNA)</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Placenta</td><td align="center" rowspan="1" colspan="1">IRS-1 (mRNA)</td><td align="center" rowspan="1" colspan="1">Decrease</td><td align="center" rowspan="1" colspan="1">
<italic>na</italic>
</td><td align="center" rowspan="1" colspan="1">[<xref rid="B103" ref-type="bibr">103</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>AMPK: adenosine monophosphate protein kinase; AMPK-Thr<sup>172</sup>: AMPK phosphorylated at threonine 172; S6K1: S6 kinase 1; S6K1-Thr<sup>421</sup>/Ser<sup>424</sup>: S6K1 phosphorylated at threonine 421 and serine 424; S6K1-Thr<sup>389</sup>: S6K1 phosphorylated at threonine 389; JNK: c-Jun N-terminal kinases; JNK-Thr<sup>183</sup>/Tyr<sup>185</sup>: JNK phosphorylated at threonine 183 and tyrosine 185; mTOR: mammalian target of rapamycin; IRS-1: insulin receptor substrate 1; IRS-1-Tyr<sup>465</sup>: IRS-1 phosphorylated at tyrosine 465; IRS-1-Ser<sup>312</sup>: IRS-1 phosphorylated at serine 312; IRS-2: insulin receptor substrate 2; IRS-2-Ser<sup>731</sup>: IRS-2 phosphorylated at serine 731; EOPE: early-onset preeclampsia; LOPE: late-onset preeclampsia; p44/42<sup>mapk</sup>: 44 and 42&#x02009;kDa mitogen-activated protein kinases; p44/42<sup>mapk</sup>-Thr<sup>202/204</sup>: p44<sup>mapk</sup> phosphorylated at threonine 202 and p42<sup>mapk</sup> phosphorylated at threonine 204; Akt: protein kinase B/Akt; Akt-Ser<sup>473</sup>: Akt phosphorylated at serine 473; eNOS: endothelial nitric oxide synthase; eNOS-Thr<sup>495</sup>: eNOS phosphorylated at threonine 495; eNOS-Ser<sup>1177</sup>: eNOS phosphorylated at serine 1177; IRs: insulin receptors; IR-A: insulin receptor A; IR-B: insulin receptor B; <italic>&#x003b2;</italic>-IR: insulin receptor <italic>&#x003b2;</italic>-subunit; PI3K: phosphatidylinositol 3 kinase; PI3K p85<italic>&#x003b1;</italic>: p85<italic>&#x003b1;</italic> regulatory subunit of PI3K; PI3K p110: p110 catalytic subunit of PI3K; EGFR: epidermal growth factor receptor; mTOR-Ser<sup>2448</sup>: mTOR phosphorylated at serine 2448; S6K1-Tyr<sup>389</sup>: S6K1 phosphorylated at threonine 389; 4EBP1: eukaryotic translation initiation factor 4E binding protein 1; 4EBP1-Thr<sup>37/46</sup>: 4EBP1 phosphorylated at threonine 37 and 46; TNF-<italic>&#x003b1;</italic>: tumour necrosis factor <italic>&#x003b1;</italic>; AP1: activator protein 1; NF-<italic>&#x003ba;</italic>B: nuclear factor-kappa B; ET-1: endothelin 1; ET<sub>A</sub>: endothelin receptor type A; ET<sub>B</sub>: endothelin receptor type B; IL-1<italic>&#x003b2;</italic>: interleukin 1<italic>&#x003b2;</italic>; hCAT-1: human cationic amino acid transporter 1; hENT1: human equilibrative nucleoside transporters 1; hENT2: human equilibrative nucleoside transporters 2; HUVECs: human umbilical vein endothelial cells; hPMECs: human placental microvascular endothelial cells. <sup>&#x02217;</sup>Cells incubated with insulin in the presence of ZM-241385 (A<sub>2A</sub>AR antagonist). <sup>&#x02217;&#x02217;</sup>GDM mothers were obese. <sup>&#x02217;&#x02217;&#x02217;</sup>Results include GDM mother under diet and insulin therapy. <sup>&#x02217;&#x02217;&#x02217;&#x02217;</sup>GDM mother on oral insulin-sensitizing antidiabetic undefined medication. <italic>na</italic>: not assayed.</p></fn></table-wrap-foot></table-wrap></floats-group></article>